Vorinostat (SAHA)

For research use only. Not for use in humans.

目录号：S1047 别名： MK0683 中文名称：伏立诺他

CAS No. 149647-78-9

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683)是一种HDAC抑制剂，无细胞试验中IC50为~10 nM。Vorinostat 会抑制高效的HPV-18 DNA扩增。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1558.77	现货
200mg	RMB 1198.15	现货
500mg	RMB 1794.86	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Vorinostat (SAHA)发表文献396篇：

Cell, 2020, S0092-8674(20)31394-5

PubMed: 33147445 ( click the link to review the publication )

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(4):599-617 e7

PubMed: 32243837 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2018, 174(3):536-548.e21

PubMed: 29961578 ( click the link to review the publication )

Cell Metab, 2018, 5;27(6):1294-1308.e7

PubMed: 29754954 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Med, 2015, 21(10):1163-71

PubMed: 26390243 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cell, 2014, 28;158(5):989-999.

PubMed: 25131989 ( click the link to review the publication )

Nature, 2011, 10;471(7337):235-9.

PubMed: 21390130 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

J Enzyme Inhib Med Chem, 2021, 36(1):34-47

PubMed: 33100043 ( click the link to review the publication )

Sci China Life Sci, 2021, 10.1007/s11427-020-1855-4

PubMed: 33420926 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(21):2001364

PubMed: 33173727 ( click the link to review the publication )

Sci Adv, 2020, 6(33):eaba6617

PubMed: 32851167 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa088

PubMed: 32107550 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

J Immunother Cancer, 2020, 8(2)e001037

PubMed: 33158915 ( click the link to review the publication )
J Immunother Cancer, 2020, 8(1)

PubMed: 31940587 ( click the link to review the publication )

Theranostics, 2020, 1;10(3):1433-1453

PubMed: 31938073 ( click the link to review the publication )

Cancer, 2020, 1;126(9):2024-2033

PubMed: 31999837 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Clin Epigenetics, 2020, 12(1):13

PubMed: 31941522 ( click the link to review the publication )

Br J Cancer, 2020, 27

PubMed: 32336756 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 17;8:158

PubMed: 32258036 ( click the link to review the publication )

J Neuroinflammation, 2020, 22;17(1):125

PubMed: 32321538 ( click the link to review the publication )

ACS Infect Dis, 2020, 29

PubMed: 32347704 ( click the link to review the publication )

Cancer Sci, 2020, 111(12):4429-4441

PubMed: 33043499 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:296

PubMed: 32195191 ( click the link to review the publication )

J Virol, 2020, 4;94(10) pii: e01923-19

PubMed: 32161174 ( click the link to review the publication )

Biochem Pharmacol, 2020, 3;178:114067

PubMed: 32504550 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

HIV Med, 2020, 21(11):747-757

PubMed: 33369029 ( click the link to review the publication )

Am J Transl Res, 2020, 12(10):6187-6203

PubMed: 33194023 ( click the link to review the publication )

Andrology, 2020, 10.1111/andr.12922

PubMed: 33064925 ( click the link to review the publication )

BMC Microbiol, 2020, 20(1):28

PubMed: 32028887 ( click the link to review the publication )

PLoS One, 2020, 15;15(5):e0232985

PubMed: 32413049 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

J Med Invest, 2020, 67(3.4):343-350

PubMed: 33148913 ( click the link to review the publication )
Sci Rep, 2020, 10(1):12864

PubMed: 32733053 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):460-468

PubMed: 31897159 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2020, 188:110753

PubMed: 31884084 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(4):615-627

PubMed: 32322466 ( click the link to review the publication )

Cancer Sci, 2020, 111(7):2374-2384

PubMed: 32391602 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01394-w

PubMed: 32709923 ( click the link to review the publication )

Viruses, 2020, 12(10)E1067

PubMed: 32977702 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01408-7

PubMed: 32733069 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01191-y

PubMed: 33250513 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Genes Dev, 2020, 34(5-6):428-445

PubMed: 32001510 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:4429-4439

PubMed: 32606937 ( click the link to review the publication )

Biomater Sci, 2020, 10.1039/d0bm00119h

PubMed: 32706009 ( click the link to review the publication )

Cell Cycle, 2020, 1-16

PubMed: 32807015 ( click the link to review the publication )

Life Sci, 2020, 248:117469

PubMed: 32109485 ( click the link to review the publication )

Chin Med J (Engl), 2020, 5;133(11):1304-1311

PubMed: 32452893 ( click the link to review the publication )

Pharmaceuticals (Basel), 2020, 13(11)E345

PubMed: 33121173 ( click the link to review the publication )

Pharm Biol, 2020, 58(1):231-238

PubMed: 32202448 ( click the link to review the publication )

PLoS Biol, 2020, 18(12):e3000941

PubMed: 33264286 ( click the link to review the publication )

PLoS Biol, 2020, 18(11):e3000981

PubMed: 33253182 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )
Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cancer Res, 2019, 79(7):1658-1670

PubMed: 30737231 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30652970 ( click the link to review the publication )

Int J Cancer, 2019, 145(9):2496-2508

PubMed: 30963560 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)E645

PubMed: 31083396 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Clin Epigenetics, 2019, 11(1):85

PubMed: 31142371 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):4

PubMed: 30642362 ( click the link to review the publication )

Oncologist, 2019, 24(8):e740-e748

PubMed: 30696721 ( click the link to review the publication )

Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656155

PubMed: 31423895 ( click the link to review the publication )

Epigenetics, 2019, 14(8):791-803

PubMed: 31088315 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Hum Mol Genet, 2019, 10.1093/hmg/ddz254

PubMed: 31691806 ( click the link to review the publication )

Pharmacol Res, 2019, 139:524-534

PubMed: 30366100 ( click the link to review the publication )
Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14935

PubMed: 31811660 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

Bone, 2019, 125:112-121

PubMed: 31100533 ( click the link to review the publication )

Front Cell Neurosci, 2019, 13:468

PubMed: 31708743 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(13)

PubMed: 31269745 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2019, 22(8):523-527

PubMed: 31179497 ( click the link to review the publication )

NMR Biomed, 2019, 32(2):e4044

PubMed: 30561869 ( click the link to review the publication )

Cancer Biol Ther, 2019,

PubMed: 30142009 ( click the link to review the publication )

Stem Cells Dev, 2019, 28(7):438-453

PubMed: 30667343 ( click the link to review the publication )

Chem Biol Interact, 2019, 306:54-61

PubMed: 30958996 ( click the link to review the publication )

Gene Ther, 2019, 26(3-4):75-85

PubMed: 30538307 ( click the link to review the publication )

Cancer Med, 2019, 8(14):6383-6392

PubMed: 31456359 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0218382

PubMed: 31206526 ( click the link to review the publication )

ACS Omega, 2019, 4(22):19895-19904

PubMed: 31788622 ( click the link to review the publication )

Exp Hematol, 2019, 72:60-71

PubMed: 30769020 ( click the link to review the publication )

Nucl Med Biol, 2019, 74-75:1-11

PubMed: 31421440 ( click the link to review the publication )

Alcohol, 2019, 78:79-87

PubMed: 30851364 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3579-3584

PubMed: 31262882 ( click the link to review the publication )
Neoplasma, 2019, 66(1):20-27

PubMed: 30509083 ( click the link to review the publication )

Res Vet Sci, 2019, 126:207-212

PubMed: 31610471 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

Thyroid, 2019, 29(5):726-734

PubMed: 30760120 ( click the link to review the publication )

Medicina (Kaunas), 2019, 55(2)

PubMed: 30700046 ( click the link to review the publication )

Adipocyte, 2019, 8(1):292-303

PubMed: 31322450 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1007-1018

PubMed: 30431129 ( click the link to review the publication )

Chin J Dent Res, 2019, 22(4):221-227

PubMed: 31859282 ( click the link to review the publication )

Front Neurol, 2019, 10:893

PubMed: 31481925 ( click the link to review the publication )

Cell Host Microbe, 2018, 24(5):689-702

PubMed: 30344003 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Cancer Res, 2018, 78(10):2705-2720

PubMed: 29490948 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

Haematologica, 2018, 103(4):679-687

PubMed: 29305415 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 432:121-131

PubMed: 29890207 ( click the link to review the publication )

Acta Biomater, 2018, 71:261-270

PubMed: 29526828 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):153

PubMed: 30012171 ( click the link to review the publication )

PLoS Pathog, 2018, 14(6):e1007061

PubMed: 29879225 ( click the link to review the publication )

Oncoimmunology, 2018,

PubMed: 30377559 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Cancer Sci, 2018, 109(8):2520-2531

PubMed: 29917299 ( click the link to review the publication )
J Virol, 2018, 92(10)

PubMed: 29343578 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(5):2600-2611

PubMed: 29461008 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3875

PubMed: 29497113 ( click the link to review the publication )

Front Microbiol, 2018, 9:2022

PubMed: 30283406 ( click the link to review the publication )

J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):466

PubMed: 29695239 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):264-270

PubMed: 29115632 ( click the link to review the publication )

Ann Hematol, 2018, 97(5):839-849

PubMed: 29359239 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):481-486

PubMed: 29505792 ( click the link to review the publication )

AAPS PharmSciTech, 2018, 19(2):634-647

PubMed: 28948528 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

J Med Virol, 2018, 90(9):1478-1485

PubMed: 29704439 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

JCI Insight, 2018, 3(4)95824

PubMed: 29467324 ( click the link to review the publication )

Sci Adv, 2018, 4(9):eaar4666

PubMed: 30263952 ( click the link to review the publication )

JCI Insight, 2018, 3(22)125568

PubMed: 30429379 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(1):47-54

PubMed: 27870832 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )
Proc Natl Acad Sci USA, 2017,

PubMed: 28673995 ( click the link to review the publication )

Haematologica, 2017, 102(4):736-745

PubMed: 27979926 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3084-3096

PubMed: 27993968 ( click the link to review the publication )

Oncogene, 2017, 36(34):4859-4874

PubMed: 28414307 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(20):3608-3622

PubMed: 28749535 ( click the link to review the publication )

Sci Signal, 2017, 10(508)eaan8355

PubMed: 29208683 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2570

PubMed: 28125090 ( click the link to review the publication )

Cell Death Dis, 2017,

PubMed: 29022919 ( click the link to review the publication )

Mol Ther Oncolytics, 2017,

PubMed: 28812060 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(11):1356-1367.e8

PubMed: 28943357 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

Eur J Med Chem, 2017, 141:596-602

PubMed: 29102179 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1485-1492

PubMed: 28498513 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

Sci Rep, 2017, 7(1):11547

PubMed: 28912522 ( click the link to review the publication )

J Biol Chem, 2017, 292(12):5043-5054

PubMed: 28167529 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Pharm Res, 2017, 34(3):668-679

PubMed: 28101809 ( click the link to review the publication )

Cancer Res Treat, 2017, 49(2):374-386

PubMed: 27488871 ( click the link to review the publication )

Cancer Med, 2017, 6(11):2673-2685

PubMed: 29024573 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )
Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:88-95

PubMed: 28323055 ( click the link to review the publication )

Am J Surg, 2017, 213(4):645-651

PubMed: 28007318 ( click the link to review the publication )

Nucleus, 2017, 8(5):515-533

PubMed: 28696859 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(28):45687-45697

PubMed: 28537899 ( click the link to review the publication )

Oncotarget, 2017, 9(1):512-523

PubMed: 29416632 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51429-51446

PubMed: 28881658 ( click the link to review the publication )

CPT Pharmacometrics Syst Pharmacol, 2017, 6(11):756-764

PubMed: 29045072 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2290

PubMed: 28536458 ( click the link to review the publication )

Oncotarget, 2017, 8(45):78480-78495

PubMed: 29108243 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103797-103814

PubMed: 29262601 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423644 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Bioorg Med Chem, 2017, 25(7):2105-2132

PubMed: 28259528 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29371976 ( click the link to review the publication )

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):569-579

PubMed: 28494238 ( click the link to review the publication )

Ann Oncol, 2016, 27(3):508-13

PubMed: 26658891 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2376-83

PubMed: 26941288 ( click the link to review the publication )
Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Drug Discov Today, 2016, 21(9):1553-1560

PubMed: 27371506 ( click the link to review the publication )

mBio, 2016, 7(6)

PubMed: 27803184 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Oncoimmunology, 2016,

PubMed: 27471639 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1364-75

PubMed: 27196750 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(6):2076-92

PubMed: 27067055 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(10):2685-2692

PubMed: 27459069 ( click the link to review the publication )

Neuropharmacology, 2016, 107:111-121

PubMed: 26970016 ( click the link to review the publication )

Biochem Pharmacol, 2016, 102:130-140

PubMed: 26718586 ( click the link to review the publication )

Sci Rep, 2016, 6:38219

PubMed: 27910887 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

J Biol Chem, 2016, 291(19):10131-47

PubMed: 27022024 ( click the link to review the publication )

Neurochem Int, 2016, 96:24-31

PubMed: 27103167 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2016, 311(5):H1139-H1149

PubMed: 27638876 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Anal Bioanal Chem, 2016, 408(13):3547-53

PubMed: 26968571 ( click the link to review the publication )

BMC Cancer, 2016, 16:667

PubMed: 27549189 ( click the link to review the publication )

Biol Chem, 2016,

PubMed: 26431101 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

Med Oncol, 2016, 33(2):11

PubMed: 26732474 ( click the link to review the publication )

Inflammation, 2016, 39(1):39-46

PubMed: 26228975 ( click the link to review the publication )

PLoS One, 2016, 11(8):e0160826

PubMed: 27536989 ( click the link to review the publication )
PLoS One, 2016, 11(1):e0145985

PubMed: 26726879 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(3):692-9

PubMed: 26084206 ( click the link to review the publication )

Asian Pac J Trop Med, 2016, 9(6):572-6

PubMed: 27262069 ( click the link to review the publication )

Genet Mol Res, 2016, 15(4)

PubMed: 27819724 ( click the link to review the publication )

Oncotarget, 2016, 7(42):68360-68370

PubMed: 27588392 ( click the link to review the publication )

Oncotarget, 2016, 8(62):104733-104744

PubMed: 29285209 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26824319 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58142-58147

PubMed: 27494885 ( click the link to review the publication )

Sci Rep, 2016, 6:21678

PubMed: 26902929 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Nat Commun, 2015, 6:7888

PubMed: 26223951 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Cancer Res, 2015,

PubMed: 26294211 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

EBioMedicine, 2015, 3:108-121

PubMed: 26870822 ( click the link to review the publication )

Cancer Lett, 2015, 356(2 Pt B):828-36

PubMed: 25449774 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:33

PubMed: 25888415 ( click the link to review the publication )
Cell Death Dis, 2015, 6:e1692

PubMed: 25766331 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1657

PubMed: 25695609 ( click the link to review the publication )

Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389 ( click the link to review the publication )

Endocr Relat Cancer, 2015, 22(5):777-92

PubMed: 26206775 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: 25284154 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(4):1337-52

PubMed: 26101701 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(10):2316-24

PubMed: 26162280 ( click the link to review the publication )

Neuropharmacology, 2015, 99:67-78

PubMed: 26188143 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Biochem Pharmacol, 2015, 94(2):79-90

PubMed: 25600908 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Apoptosis, 2015, 20(7):975-85

PubMed: 25835755 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(39):23725-37

PubMed: 26269591 ( click the link to review the publication )

J Biol Chem, 2015, 290(3):1829-36

PubMed: 25492871 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15(1):273

PubMed: 25880212 ( click the link to review the publication )

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0130339

PubMed: 26091518 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0139740

PubMed: 26466379 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134825

PubMed: 26284517 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143897

PubMed: 26623653 ( click the link to review the publication )
J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901 ( click the link to review the publication )

J Biomol Screen, 2015, 20(10):1286-93

PubMed: 26384394 ( click the link to review the publication )

Mol Vis, 2015, 21:502-14

PubMed: 25999677 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):4291-4297

PubMed: 26095064 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Circ Heart Fail, 2015, 8(6):1094-104

PubMed: 26371176 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Acta Neuropathol, 2014, 128(2):291-303

PubMed: 24839957 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930 ( click the link to review the publication )

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207 ( click the link to review the publication )

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245 ( click the link to review the publication )

Oncogene, 2014, 33(25):3307-15

PubMed: 23995789 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394 ( click the link to review the publication )

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed: ( click the link to review the publication )

Cancer Cell Int, 2014, 14(1):112

PubMed: 25546354 ( click the link to review the publication )
Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401 ( click the link to review the publication )

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122 ( click the link to review the publication )

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691 ( click the link to review the publication )

Virology, 2014, 462-463:328-39

PubMed: 25014309 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(3):305-16

PubMed: 24351423 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):373

PubMed: 24886166 ( click the link to review the publication )

FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544 ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Oncotarget, 2014, 5(14):5637-50

PubMed: 25026298 ( click the link to review the publication )

Pharmacol Res Perspect, 2014, 2(3):e00043

PubMed: 25505589 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Cytometry A, 2014, 85(1):78-87

PubMed: 24038859 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389 ( click the link to review the publication )

Blood, 2013, 14;121(11):2038-50

PubMed: 23327920 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Res, 2013, 73(8):2428-34

PubMed: 23382048 ( click the link to review the publication )
Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001 ( click the link to review the publication )

Neuropsychopharmacology, 2013, 38(9):1674-84

PubMed: 23474591 ( click the link to review the publication )

Oncogene, 2013, 33(33):4265-72

PubMed: 24292675 ( click the link to review the publication )

Oncogene, 2013, 32(10):1316-29

PubMed: 22543582 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e733

PubMed: 23868066 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 160(2):188-98

PubMed: 23167276 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

Apoptosis, 2013, 18(11):1348-1362

PubMed: 23708756 ( click the link to review the publication )

J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

PLoS Comput Biol, 2013, 9(2):e1002887

PubMed: 23408876 ( click the link to review the publication )

Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107 ( click the link to review the publication )

Front Pharmacol, 2013, 4:44

PubMed: 23596417 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Cell Cycle, 2013, 12(13):2073-83

PubMed: 23759592 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66130

PubMed: 23762475 ( click the link to review the publication )

PLoS One, 2013, 8(1):e53766

PubMed: 23320102 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Blood, 2012, 8;120(19):3958-67

PubMed: 22983447 ( click the link to review the publication )

J Exp Med, 2012, 209(1):35-50

PubMed: 22231305 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731 ( click the link to review the publication )
Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857 ( click the link to review the publication )

Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545 ( click the link to review the publication )

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764 ( click the link to review the publication )

FASEB J, 2012, 26(7):3032-41

PubMed: 22459148 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329 ( click the link to review the publication )

J Biol Chem, 2012, 287(43):36609

PubMed: 22952229 ( click the link to review the publication )

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110 ( click the link to review the publication )

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885 ( click the link to review the publication )

Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140 ( click the link to review the publication )

Oncol Rep, 2012, 28(1):105-10

PubMed: 22484732 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40684

PubMed: 22808232 ( click the link to review the publication )

PLoS One, 2012, 7(9):e44265

PubMed: 22957056 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52335

PubMed: 23272238 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52753

PubMed: 23300762 ( click the link to review the publication )

Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617 ( click the link to review the publication )

Biochem Biophys Res Co, 2012, 420(2):325-30

PubMed: 22425986 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681 ( click the link to review the publication )
Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

J Transl Med, 2011, 9:37

PubMed: 21477288 ( click the link to review the publication )

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324 ( click the link to review the publication )

Mol Med, 2011, 17(5-6):466-72

PubMed: 21424110 ( click the link to review the publication )

PLoS One, 2011, 6(6):e21382

PubMed: 21738649 ( click the link to review the publication )

PLoS One, 2011, 6(7):e22739

PubMed: 21818379 ( click the link to review the publication )

BMC Neurosci, 2011, 12:50

PubMed: 21615950 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454 ( click the link to review the publication )

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733 ( click the link to review the publication )

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683)是一种HDAC抑制剂，无细胞试验中IC50为~10 nM。Vorinostat 会抑制高效的HPV-18 DNA扩增。

特性

Vorinostat是广谱HDAC活性抑制剂，抑制I和II类酶。

靶点

HDAC ^[1]
(Cell-free assay)

~10 nM

体外研究

Vorinostat是小分子量（<300）线性肟酸，抑制HDAC活性，包括乙酰化组蛋白和非组蛋白的积累，抑制培养细胞的增殖，且抑制肿瘤生长。Vorinostat通过结合到酶的活性位点而抑制 HDAC活性。Vorinostat 抑制多种转化细胞增殖（包括淋巴瘤，多发性骨髓瘤，白血病，和非小细胞肺癌），与对照组相比抑制生长达50% 时的浓度为0.5 到10μM。Vorinostat作用于淋巴瘤和白血病细胞，包括 Burkitt, B-细胞急性淋巴细胞白血病 (B-ALL), MCL, DLBCL, ATL和T-细胞，不同程度抑制细胞增殖。除了抑制转化细胞增殖, Vorinostat 也抑制正常细胞增殖，通过比较Vorinostat 作用于一组细胞系–正常人非纤维细胞(WI-38)和 SV40巨大T抗原转化WI-38(VA-13细胞)而得到证明。Vorinostat 抑制两种类型细胞增殖，这种作用存在剂量依赖性。但发现Vorinostat 对转化细胞具有选择毒性，包括使肿瘤细胞死亡，而对正常细胞只起抑制作用，不会使其死亡。^[1] Genistein 和Vorinostat 联用效果比5-aza和Vorinostat 联用作用于诱导细胞死亡有效很多。Genistein和Vorinostat联用作用于ARCaP-E使增殖降低 80 %，作用于ARCaP-M细胞，增殖降低60 %以上。Genistein和Vorinostat 联用抑制细胞增殖具有协同效应。作用于ARCaP-E 细胞(820个基因诱导和1046个基因抑制) ARCaP-M 细胞，Vorinostat比Genistein 影响更多基因。^[2] Vorinostat作用于肿瘤细胞表面，提高Fas蛋白水平，这种作用存在剂量依赖性，且按0.75 μM剂量处理，提高达到一个稳定水平。^[3] Vorinostat 抑制肿瘤细胞生长，包括NB4, H460 和HCT-116，IC50分别为0.7μM, 3.4μM和1.2 μM。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
H1299	MUHLbY5ie2ViQYPzZZk>		MofTNlAhdWmw	NXLBWWF3TE2VTx?=	NV3TOpF{UW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KEiGQVOg[Y57gW2nIIfpeIghUUN3MDDv[kAxNjF7NDFOwG0>	NYDMUllRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1NlE1OjJpPkG0OVIyPDJ{PD;hQi=>
HT1080	NEXXR41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHPpUWg4OiCq	M3GxemROW09?	M2Lwb2lEPTB;Mj60JO69VQ>?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjJ5MEG3OUc,OTJ{N{CxO\|U9N2F-
K562	NGDSPZJMcW6jc3WgRZN{[Xl?		MnXLOkBp	M1jwPGROW09?	NFXQfnlKdmirYnn0bY9vKG:oIHj1cYFvKGirc4TvcoUh\GWjY3X0fYxie2ViKH3pfJR2emVib3[gTGRCSzFiYX7kJGhFSUN{KTD3bZRpKEmFNUCgc4YhOC5yMTFOwG0>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjRzOUO4NEc,OTJ2MUmzPFA9N2F-
A20	NInYfVNMcW6jc3WgRZN{[Xl?		NHLsfmMyKGh?	M3fPRWROW09?	MkD4ZY51cS2KRFHDNUBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xNVIh\|ryP	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTl4MES4PUc,OTF7NkC0PFk9N2F-
Friend leukemic cell	M3nwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWe2bW45PTBizszN	MoTLO\|IhcA>?	NHzMbWxFVVOR	MWXJR\|UxRTBwOUmg{txO	NEKyUY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkGwPVkyOyd-MUKxNFk6OTN:L3G+
H1299	MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGfXTlA4OiCq	MlLRSG1UVw>?	M{TtdWlEPTB;Nz6yOEDPxE1?	M2SySlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUKxOFIzLz5zNEWyNVQzOjxxYU6=
HeLa	NUXvelluU2mwYYPlJGF{e2G7		MV2zNEBucW5?		NHj3c4pKdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6\|dDDobZN1d26nIHTlZYNmfHmuYYPlJJdqfGhiSVO1NEBw\iByLkK4JO69VQ>?	M4jqN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkCzPVQ6Lz5zNU[wN\|k1QTxxYU6=
LOX-IMVI	MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVTkWI97PDhiaB?=		MkDrTWM2OD1zLkOg{txO	M3XQUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3N{G1OFcxLz5zNUexOVQ4ODxxYU6=
NCI-H226	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHvMV\|Y1QCCq		NXG0SHM1UUN3ME2yMlYh\|ryP	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTdzNUS3NEc,OTV5MUW0O\|A9N2F-
RXF-631L	Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWW0PEBp		MWjJR\|UxRTJizszN	M13RelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3N{G1OFcxLz5zNUexOVQ4ODxxYU6=
SNB-78	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYG0PEBp		M{\uc2lEPTB;MU[g{txO	MoPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV5MUW0O\|AoRjF3N{G1OFcxRC:jPh?=
St-4	NHvQVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4LCNVQ5KGh?		NWO2bndqUUN3ME21MlIh\|ryP	NUjzbWdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW3NVU1PzBpPkG1O\|E2PDdyPD;hQi=>
ARP1	NHrvTY5HfW6ldHnvckBCe3OjeR?=	NXz0V2J4OiEQvF2=	MWm2JIg>		Mlz2TY5lfWO2aX;uJI9nKFB{MWfBSlEh\2WwZTDlfJBz\XO\|aX;u	NEn0Z2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNEezOFgxPid-MUS3N\|Q5ODZ:L3G+
CEM	MWnLbY5ie2ViQYPzZZk>		MnvxNUBp	M4joXmROW09?	MUDJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwM{Og{txO	NWe3ZnNJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NlAxPjRpPkG2OFIxODZ2PD;hQi=>
HCT15	NYLrNZlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{TjdlQ5KGh?		NX3LWotrT0l3ME2wMlgzKM7:TR?=	NUTjT3lbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3NlMzOjdpPkG2O\|I{OjJ5PD;hQi=>
NCI-H23	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWnSeI5sPDhiaB?=		MU\HTVUxRTBwOUKg{txO	NVXuNHdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3NlMzOjdpPkG2O\|I{OjJ5PD;hQi=>
GM15850	NFPtUZhMcW6jc3WgRZN{[Xl?	MkXvNk42KM7:TR?=	MYW5OkBp	NXTk[4dtTE2VTx?=	MorNTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSEOgcJl{cW6nIEG0JIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n	NGLobYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkmyNVM3Pyd-MU[5NlE{Pjd:L3G+
GM15850	M1G2SmtqdmG\|ZTDBd5NigQ>?	MUmyMlUh\|ryP	MmXVPVYhcA>?	NH3RbWVFVVOR	NWjTblFUUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFUh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NILEPG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkmyNVM3Pyd-MU[5NlE{Pjd:L3G+
GM15850	NF\QVXVMcW6jc3WgRZN{[Xl?	M3PycFIvPSEQvF2=	MlPmPVYhcA>?	NHTpdFRFVVOR	MonCTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEGyJIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n	MkT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7MkGzOlcoRjF4OUKxN\|Y4RC:jPh?=
GM15850	NFPHU49McW6jc3WgRZN{[Xl?	MYeyMlUh\|ryP	MYG5OkBp	MX7EUXNQ	NVjjVXdKUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NH;RUnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkmyNVM3Pyd-MU[5NlE{Pjd:L3G+
GM15850	NYXnUoV1U2mwYYPlJGF{e2G7	MV[yMlUh\|ryP	NX;ZXZhxQTZiaB?=	NIDGXnFFVVOR	M4TuOmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFi0JIx6e2mwZTC4JIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n	NVfCNnE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NlE{PjdpPkG2PVIyOzZ5PD;hQi=>
GM15850	MV7LbY5ie2ViQYPzZZk>	MUeyMlUh\|ryP	Mom1PVYhcA>?	NHHrdo1FVVOR	MULJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViMU[gZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	Mn\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7MkGzOlcoRjF4OUKxN\|Y4RC:jPh?=
U937	M{S4WmZ2dmO2aX;uJGF{e2G7	NWTvSYZOPSEQvF2=	NILIWYwzPCCq	MULEUXNQ	MkfGR4VtdCCleXPs[UBienKnc4SgZpkh[WOldX31cIF1cW:wIHH0JHMwTzJxTTDwbIF{\Q>?	M2P0XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MEC0O\|E5Lz5zN{CwOFcyQDxxYU6=
H661	M3P4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEjQSJo1QCCq		NYXBboh4UUN3ME2xJO69VQ>?	NGDYdpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{G1O\|AxQSd-MUexOVcxODl:L3G+
U937	Mmi4SpVv[3Srb36gRZN{[Xl?	NHzQUms2KM7:TR?=	M4faOFI1KGh?	Mn;DSG1UVw>?	NXXsZ25GUW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDhZ4V1gWyjdHnvci=>	NWD6UI1IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0OFc4PTBpPkG3OFQ4PzVyPD;hQi=>
U937	M4ToWmZ2dmO2aX;uJGF{e2G7	NIewNW8yKM7:TR?=	Mn;hNlQhcA>?	NHHKbXFFVVOR	MXTF[oZm[3Rib36gZYxxcGFidIXieYxqdiCjY3X0fYxifGmxbh?=	NE\KWVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S0O\|c2OCd-MUe0OFc4PTB:L3G+
RAW264.7	Moq5SpVv[3Srb36gRZN{[Xl?	M{C2dFExKM7:TR?=	MnvrNlRp	NEHkclZ4[XSnch?=	MnnpTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBVVk[jbIDoZUBxem:mdXP0bY9vKHerdHigTWM2OCCxZjCwMlc3KM7:TR?=	NF\aeGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S3O\|UyQCd-MUe0O\|c2OTh:L3G+
RAW264.7	M2PRUGZ2dmO2aX;uJGF{e2G7	M2P2fFExKM7:TR?=	MoD5NlRp	NXjRbXZ1f2G2ZYK=	M{XCVWlvcGmkaYTpc44hd2ZiTGDTMZN1cW23bHH0[YQhVk9icILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOS56ODFOwG0>	NE\FWms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S3O\|UyQCd-MUe0O\|c2OTh:L3G+
SC9	M3Lp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXO0PEBp		MVTJR\|UxRTBwNkC2JO69VQ>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzVyN{KxPUc,OTd3MEeyNVk9N2F-
ST14A	Mn;mSpVv[3Srb36gRZN{[Xl?	MV61JI5O	MVW3NkBp		MXHJcoNz\WG\|ZTDpckBTTVOWL17SV2YhdVKQQTDlfJBz\XO\|aX;u	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4NUm5N{c,OTd3NkW5PVM9N2F-
ST14A	NX\UN5N4TnWwY4Tpc44hSXO\|YYm=	NHvE[pg2KG6P	NVOxephxPzJiaB?=		MXPJcoNz\WG\|ZTDpckBGOkZzIH3SUmEh\XiycnXzd4lwdg>?	NYDFXXFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OlU6QTNpPkG3OVY2QTl\|PD;hQi=>
PANC1	MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofwNUDPxE1?			MoTwTWM2OD1yLkS1JO69VQ>?	NHLPbnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W4PFc1PCd-MUe1PFg4PDR:L3G+
PANC1	NW\1bZpPTnWwY4Tpc44hSXO\|YYm=	NFThdWcyKM7:TR?=	NX;KUnJlOjRiaB?=		M4WwVWlv[3KnYYPlJIlvKHB{MWfBSlEwS0mSMTDn[Y5mKGW6cILld5Nqd25?	MojPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3OEi3OFQoRjF5NUi4O\|Q1RC:jPh?=
PANC1	MlXVSpVv[3Srb36gRZN{[Xl?	MXuxJO69VQ>?	MmDlNlQhcA>?		NXf1OZRTUW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44>	NX7ETmI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1PFg4PDRpPkG3OVg5PzR2PD;hQi=>
PT45	MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTWPZROUUN3ME20JO69VQ>?	MkDNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3OEi3OFQoRjF5NUi4O\|Q1RC:jPh?=
ACHN	M4f6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWjV[mF7OjFiaB?=		NWmzNohST0l3ME2wMlY2KM7:TR?=	NE\wR5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[2NlYxPid-MUe2OlI3ODZ:L3G+
PC3	M13DSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXnZeIR5OjFiaB?=		M2nlOWdKPTB;MD63NUDPxE1?	Mo\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4NkK2NFYoRjF5Nk[yOlA3RC:jPh?=
A431	NIjkWmxEgXSxdH;4bYMhSXO\|YYm=		NX\UdnFmPzJiaB?=		M2rYVmlEPTB;ND6yJO69VQ>?	NXrZWoVkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2PVE4PjNpPkG3OlkyPzZ\|PD;hQi=>
Cal27	MYXDfZRwfG:6aXOgRZN{[Xl?		MYS3NkBp		MWHJR\|UxRTNwMjFOwG0>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ7MUe2N{c,OTd4OUG3OlM9N2F-
CCRF-CEM	MXjDfZRwfG:6aXOgRZN{[Xl?		MmDFO\|IhcA>?		NH\QPIpKSzVyPUCuPEDPxE1?	NUX3bphPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2PVE4PjNpPkG3OlkyPzZ\|PD;hQi=>
EOL1	MYfDfZRwfG:6aXOgRZN{[Xl?		NXznUm9qPzJiaB?=		NFXPTZVKSzVyPUGg{txO	M2nXelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkmxO\|Y{Lz5zN{[5NVc3OzxxYU6=
Hec-1-A	M{\rfmN6fG:2b4jpZ{BCe3OjeR?=		NIfSVpU4OiCq		NWHyVnBqUUN3ME2xJO69VQ>?	MmrJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4OUG3OlMoRjF5NkmxO\|Y{RC:jPh?=
HeLa	M4LEWGtqdmG\|ZTDBd5NigQ>?	NYHkXVlPOTBizszN	NHPqS3k{OCCvaX6=	MYjEUXNQ	NFj1RmxKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGhFSUNzIIfpeIghUUN3MDDv[kAxNjB{IN88US=>	NILBb2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[5NVc3Oyd-MUe2PVE4PjN:L3G+
RKOp21	NHPyV2tEgXSxdH;4bYMhSXO\|YYm=		NE\Q[\|k4OiCq		NGDMRXpKSzVyPUGuO\|Yh\|ryP	M3vuSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkmxO\|Y{Lz5zN{[5NVc3OzxxYU6=
Saos2	NVvafllDS3m2b4TvfIlkKEG\|c3H5		NHjYOm84OiCq		MUHJR\|UxRTJwMzFOwG0>	NIn1ZXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[5NVc3Oyd-MUe2PVE4PjN:L3G+
SK-OV-3	MkHQR5l1d3SxeHnjJGF{e2G7		Moi5O\|IhcA>?		NX;jPYV5UUN3ME2yMlIh\|ryP	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ7MUe2N{c,OTd4OUG3OlM9N2F-
U87MG	NVK4OoE2S3m2b4TvfIlkKEG\|c3H5		M3rL[\|czKGh?		MWnJR\|UxRTFzIN88US=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ7MUe2N{c,OTd4OUG3OlM9N2F-
NUGC3	NF;ZflhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Tw[\|Uh\|ryP	M3i4RlI1KGh?		NEPIZVBIUTVyPUKuO\|kh\|ryP	NW\vRYtFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5NFQ5PDNpPkG3PVA1QDR\|PD;hQi=>
CCD1059SK	NVHi[JlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXTTWM2OD12Mz61JO69VQ>?	NEPGN5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0O\|U2PCd-MUiyOFc2PTR:L3G+
HepG2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDhTmQzUUN3ME2wMlAxODZizszN	M3LnRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkS3OVU1Lz5zOEK0O\|U2PDxxYU6=
HT1080	MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDmTWM2OD1yLkCwNlQh\|ryP	NFr1SZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0O\|U2PCd-MUiyOFc2PTR:L3G+
SKBR3	MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{Xwc2lEPTB;MD64JO69VQ>?	NX\i[ZhnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PTRpPkG4NlQ4PTV2PD;hQi=>
SNB78	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mli1SWM2OD1zNjFOwG0>	NVzYT4RMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PTRpPkG4NlQ4PTV2PD;hQi=>
SQ20B	M4rsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1uyS2lEPTB;MzFOwG0>	NHH5RoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0O\|U2PCd-MUiyOFc2PTR:L3G+
St4	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrXXFU{TUN3ME21MlIh\|ryP	NF[zU\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0O\|U2PCd-MUiyOFc2PTR:L3G+
MCF7	NEDkZYlHfW6ldHnvckBCe3OjeR?=	MlfFNVAh\|ryP	NHj1dGk5KGh?	NHjIS3dFVVOR	M2[5WGlv\HWldHnvckBw\iC2dXL1cIlvKGi7cHXyZYNmfHmuYYTpc44>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ4OUKyOkc,OTh{NkmyNlY9N2F-
HEK293	M{\JdmtqdmG\|ZTDBd5NigQ>?		NFvGeGsyKGh?	M3e2TWROW09?	NU\QXpVKUW6qaXLpeIlwdiCxZjDISGFEOSC5aYToJGlEPTBib3[gNE4xOyEQvF2=	MlHmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|MEi1OlMoRjF6M{C4OVY{RC:jPh?=
HEK293	NXrEe\|NjU2mwYYPlJGF{e2G7		M4rBfFEhcA>?	NXvQV\|FuTE2VTx?=	M1q0VWlvcGmkaYTpc44hd2ZiSFTBR\|Mhf2m2aDDJR\|UxKG:oIECuNFU4KM7:TR?=	M12zPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{C4OVY{Lz5zOEOwPFU3OzxxYU6=
G401	NWHa[nBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWK3NkBp	Mmn6SG1UVw>?	NVu2UHNqUUN3ME2xJO69VQ>?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN5MEO3N{c,OTh\|N{CzO\|M9N2F-
HeLa	NH:wXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4ezdVczKGh?	NWjPO3BVTE2VTx?=	NGn3XpdKSzVyPUCuOFYh\|ryP	NH7Eb4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO3NFM4Oyd-MUizO\|A{PzN:L3G+
Human renal epithelial cell	M3HPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmDmO\|IhcA>?	M{XNZmROW09?	M3rXRWlEPTB;MUSg{txO	Ml3mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|N{CzO\|MoRjF6M{ewN\|c{RC:jPh?=
U937	MmTmSpVv[3Srb36gRZN{[Xl?	NVW1[4R{PSEQvF2=	M2PC[lI1KGh?		M3faRmlv\HWldHnvckBw\iCqaYP0c45mKEh2IHj5dIVz[WOndInsZZRqd25?	Mk\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|OEGyN\|goRjF6M{ixNlM5RC:jPh?=
U937	M2HyR2Z2dmO2aX;uJGF{e2G7	M3vCUVUh\|ryP	MX6yOEBp		MUfJcoR2[3Srb36gc4Yh[WyyaHGgeJVjfWyrbjDofZBmemGlZYT5cIF1cW:w	NX3EeoR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizPFEzOzhpPkG4N\|gyOjN6PD;hQi=>
U937	NIDTS49HfW6ldHnvckBCe3OjeR?=	NXfwNYE6PSEQvF2=	NVqzdYY4OjRiaB?=		NV\ad\|BLUW6mdXP0bY9vKG:oIICyNUBmgHC{ZYPzbY9v	MkLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|OEGyN\|goRjF6M{ixNlM5RC:jPh?=
U937	NV7nPIduTnWwY4Tpc44hSXO\|YYm=	Mn36OUDPxE1?	MmfjNlQhcA>?		MVvJcoR2[3Srb36gc4Yh[XCxcITvd4l{	NWXrTpVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizPFEzOzhpPkG4N\|gyOjN6PD;hQi=>
U937	NGnLcWFHfW6ldHnvckBCe3OjeR?=	MkPtOUDPxE1?	NYfwV5R{OjRiaB?=		MmrKTY5lfWO2aX;uJI9nKGe{YX71cI9kgXSrYzDkbYZn\XKnboTpZZRqd25?	NUi0NIRJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizPFEzOzhpPkG4N\|gyOjN6PD;hQi=>
U937	NEL2W4pMcW6jc3WgRZN{[Xl?	NF;weVk2KM7:TR?=	Mn\jNlQhcA>?		MmnkTY5pcWKrdHnvckBw\iCqdX3hckBJTEGFMR?=	NH7lRWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO4NVI{QCd-MUizPFEzOzh:L3G+
U937	NU\PdXpEU2mwYYPlJGF{e2G7	NXiyT2p4PSEQvF2=	MXSyOEBp		MWTJcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN2	M13jbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{ixNlM5Lz5zOEO4NVI{QDxxYU6=
HEK-TE	NF3LdGhHfW6ldHnvckBCe3OjeR?=	MWi1JO69VQ>?	MXi2bC=>	NV\PWFQyTE2VTx?=	NHnEXJhKdmO{ZXHz[UBqdiCqaYP0c45mKEh\|IHHj[ZR6dGG2aX;u	NYG0fmxIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0N\|QyPDRpPkG4OFM1OTR2PD;hQi=>
HPDE6c7	M3u4TWN6fG:2b4jpZ{BCe3OjeR?=	MX:1NEDPxE1?	MWO3NkBp	MV3EUXNQ	NEjMRVJKSzVyPUGuN{DPxE1?	M{f2dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEm0OFY{Lz5zOES5OFQ3OzxxYU6=
Human microvascular epithelial cell	MUTDfZRwfG:6aXOgRZN{[Xl?	M{TGSVUxKM7:TR?=	MX23NkBp	M3rMOmROW09?	NH63TlFKSzVyPUGuN{DPxE1?	M3rBXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEm0OFY{Lz5zOES5OFQ3OzxxYU6=
Hup T3	MUfDfZRwfG:6aXOgRZN{[Xl?	NGnVWYk2OCEQvF2=	MVW3Nog>	MlO3SG1UVw>?	NHK0[IpKSzVyPUCuPEDPxE1?	NFnNXXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES5OFQ3Oyd-MUi0PVQ1PjN:L3G+
Mia Paca2	NX3tS5Y1S3m2b4TvfIlkKEG\|c3H5	NUHEXmR7PTBizszN	NXXJS2NNPzKq	MVHEUXNQ	NFjBSJJKSzVyPUGuNUDPxE1?	M{\kcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEm0OFY{Lz5zOES5OFQ3OzxxYU6=
Panc 04.03	MXjDfZRwfG:6aXOgRZN{[Xl?	MnrzOVAh\|ryP	MmHFO\|Jp	MWTEUXNQ	NUnCXW9FUUN3ME2xMlIh\|ryP	NXTUNlRRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0PVQ1PjNpPkG4OFk1PDZ\|PD;hQi=>
SU 86.86	M3iyemN6fG:2b4jpZ{BCe3OjeR?=	NY\zeGtUPTBizszN	NXXFTW1uPzKq	M1;PTmROW09?	MmrETWM2OD1zLkOg{txO	M1LacVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEm0OFY{Lz5zOES5OFQ3OzxxYU6=
HEK293	MYXLbY5ie2ViQYPzZZk>		NH\JN\|Q{KGh?		MWPJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFjERWM3KGW6cILld5Nqd25id3n0bEBKSzVyIH;mJFAvODF7IN88US=>	Moe4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NUi2OlkoRjF6NUW4OlY6RC:jPh?=
HeLa	NXzEb5Z2U2mwYYPlJGF{e2G7		NWXrcmN6OiCq		MVfJcohq[mm2aX;uJI9nKG63Y3zlZZIhUESDQzD3bZRpKEmFNUCgc4YhOC5yOEOg{txO	M{fOe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUW4OlY6Lz5zOEW1PFY3QTxxYU6=
RAW264.7	MlnpSpVv[3Srb36gRZN{[Xl?	M3z1N\|Ih\|ryP	M2Du[\|MvPSCq	MVPEUXNQ	NV7tV2xtSW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJIlv\mWldHXkJJdqfGhiSVO1NEBw\iByLkGxJO69VQ>?	NVnROXlZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2OFQ6PjlpPkG4OlQ1QTZ7PD;hQi=>
NB4			MXK0PIg>	NFPxbVFFVVOR	MnfqTWM2OD1yLk[g{txO	M2TwR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{KzN\|Q6Lz5zOEeyN\|M1QTxxYU6=
HEK293	NYDlNGtuTnWwY4Tpc44hSXO\|YYm=	MkjUNVAh\|ryP	NYXnRY5ZOjRiaB?=	NH\m[FRFVVOR	Mn7SRYN1cX[jdHnvckBw\iCvb4Xz[UBYdnR\|YTDzbYdv[Wyrbneg[ZhxemW\|c3Xk	MnzTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyMkK2O\|UoRjF7MEKyOlc2RC:jPh?=
HCT116	M3jhSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{\0flczcA>?	MWXEUXNQ	MnTWTWM2OD1yLkOxJO69VQ>?	NHu5S2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC4OFI6PCd-MUmwPFQzQTR:L3G+
HeLa	M2e3b2tqdmG\|ZTDBd5NigQ>?	NHfV[YozKM7:TR?=	NX\KNGp5OzBibXnu	MY\EUXNQ	M{[3[mlvcGmkaYTpc44hd2ZiSFTBR\|IhcW5iaIXtZY4hUGWOYTDj[YxteyC5aYToJGlEPTBib3[gNE4yKM7:TR?=	NFXhWVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC4OFI6PCd-MUmwPFQzQTR:L3G+
IGROV1	Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3O5OFczKGh?	M{HVOmROW09?	NELIenFKSzVyPUKuNkDPxE1?	NVvuPHl7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwPFQzQTRpPkG5NFg1Ojl2PD;hQi=>
IGROV1	MYLLbY5ie2ViQYPzZZk>	NEH3SJU2KM7:TR?=	NUH6N2hjOjRiaB?=	MVrEUXNQ	MkXETY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KHB3MzDhZ4V1gWyjdHnvci=>	NHXjUXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC4OFI6PCd-MUmwPFQzQTR:L3G+
IGROV1	Mli5T4lv[XOnIFHzd4F6	MoPjNVAh\|ryP	NHX3UJk1KGh?	MVTEUXNQ	MlnKTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGirc4TvcoUuUDRiYXPleJlt[XSrb36=	NEHpbXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC4OFI6PCd-MUmwPFQzQTR:L3G+
IGROV1	MW\LbY5ie2ViQYPzZZk>	M376SVExKM7:TR?=	NXLtNpliPCCq	NEf3[mhFVVOR	NWHwSmc4UW6qaXLpeIlwdiCxZjDISGFEPiCjc4Pld5Nm\CCjczDhcJBp[S22dXL1cIlvKGGlZYT5cIF1cW:w	M4ri[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEi0Nlk1Lz5zOUC4OFI6PDxxYU6=
T24	Mkn0T4lv[XOnIFHzd4F6		M{\yflMhcA>?		M{H4SWlv\HWldHnvckBw\iCqaYP0c45mKEh\|IHHj[ZR6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkGyJO69VQ>?	M{jtNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEi0N\|k2Lz5zOUC4OFM6PTxxYU6=
T24	NYjJS45YU2mwYYPlJGF{e2G7		MoWyN{Bp		MWPJcoR2[3Srb36gc4Yh[WyyaHGgeJVjfWyrbjDhZ4V1gWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6yOUDPxE1?	NVL5XHM5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwPFQ{QTVpPkG5NFg1Ozl3PD;hQi=>
HeLa	NUPpd5FoU2mwYYPlJGF{e2G7		MnOzNVUhdWmw	NYrNZXBHTE2VTx?=	M1[yNmlvcGmkaYTpc44hd2ZiSFTBR\|Yh\nKxbTDueYNt\WG{IHX4eJJi[3Rid3n0bEBKSzVyIH;mJFAvODh3NTFOwG0>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB7M{i4OEc,OTlyOUO4PFQ9N2F-
HeLa	Ml7FT4lv[XOnIFHzd4F6		MX[xOUBucW5?	MmrWSG1UVw>?	M4[zZmlvcGmkaYTpc44hd2ZiSFTBR\|gh\nKxbTDueYNt\WG{IHX4eJJi[3Rid3n0bEBKSzVyIH;mJFEvQDZizszN	MoPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyOUO4PFQoRjF7MEmzPFg1RC:jPh?=
NCI-H69	MX\DfZRwfG:6aXOgRZN{[Xl?		NEH6emc4OiCq	MXvEUXNQ	MlXxTWM2OD1{LkC2JO69VQ>?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB7M{i4OEc,OTlyOUO4PFQ9N2F-
SKMES1	MXzDfZRwfG:6aXOgRZN{[Xl?		M3HXTVczKGh?	Mln5SG1UVw>?	NXfmeZBDUUN3ME2yMlQzKM7:TR?=	Mkf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyOUO4PFQoRjF7MEmzPFg1RC:jPh?=
S2	NIDnbXdMcW6jc3WgRZN{[Xl?	MlvrNE4yNTFyIN88US=>	MVyxJIg>		MXvJcohq[mm2aX;uJI9nKFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDISGFEOSCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvODV7IN88US=>	MoDaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|MUe0OVAoRjF7M{G3OFUxRC:jPh?=
SHSY5Y	MlG1T4lv[XOnIFHzd4F6	NEPBPFAyOCEQvF2=	NH7WZnU1QCCq	NYXBN21kTE2VTx?=	M1XwXWlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD61JO69VQ>?	NVvPUWVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzOFQyPzVpPkG5N\|Q1OTd3PD;hQi=>
SHSY5Y	NIe3PVBEgXSxdH;4bYMhSXO\|YYm=	NGHIVFgyOCEQvF2=	NVzOWlUxPDhiaB?=	NVj0S5NuTE2VTx?=	NWfPdGQ{UUN3ME2yJO69VQ>?	Ml34QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|NESxO\|UoRjF7M{S0NVc2RC:jPh?=
DMS114	MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGrme5Q1QCCq		MkXOS2k2OD1{Lkmg{txO	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTRzOUKwOUc,OTl2MUmyNFU9N2F-
HBC5	NEHR[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIPUOoc1QCCq		M{PLN2dKPTB;MUeg{txO	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTRzOUKwOUc,OTl2MUmyNFU9N2F-
SNB78	Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV32NIR4PDhiaB?=		MWHHTVUxRTF4IN88US=>	NXP1NYZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0NVkzODVpPkG5OFE6OjB3PD;hQi=>
HeLa	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUe5PY9IPzJiaB?=	NV;0OHFMTE2VTx?=	NIDjbnFKSzVyPUCuOFYh\|ryP	NXPBUW8{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OFE5PDZpPkG5OFQyQDR4PD;hQi=>
BHK	MmPHT4lv[XOnIFHzd4F6	M4nLNlUh\|ryP	NHLDe\|YzPCCq	MW\EUXNQ	NFHvTolKdmirYnn0bY9vKG:oIFjERWM4KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBxdGG\|bXGgcYVu[nKjbnWgSoRmdHSjNUC4JGNHXFJicILveIVqdg>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTl4Nke4PUc,OTl7Nk[3PFk9N2F-
CFBE41o-	MWDLbY5ie2ViQYPzZZk>	M4fHeVUh\|ryP	NGP6T4Y5KGh?	MYDEUXNQ	Mmm2TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGi7cHXyZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SCKMx?=	M4Xwb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[2O\|g6Lz5zOUm2Olc5QTxxYU6=
CFBE41o-	M{W0RWtqdmG\|ZTDBd5NigQ>?	NVjSdYY4PSEQvF2=	M2HYRlQhcA>?	MYPEUXNQ	MYPJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5ibYX0ZY51KE[mZXz0ZVUxQCCFRmTSJJBzd3SnaX6gcIV3\Wx?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTl4Nke4PUc,OTl7Nk[3PFk9N2F-
CFBE41o-	M4T0O2tqdmG\|ZTDBd5NigQ>?	MmW2NUDPxE1?	NFLaN5UyKGh?	NWn2W2tXTE2VTx?=	MlXLTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIFPGWHIheHKxdHXpckBt\X[nbB?=	MmLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7Nk[3PFkoRjF7OU[2O\|g6RC:jPh?=
Primary bronchial epithelial cell	MXTLbY5ie2ViQYPzZZk>	NILGUmwyKM7:TR?=	MnTNNlQhcA>?	M{nHeWROW09?	NEHrSGJKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJicILveIVqdiCjcHnjZYwhe3W{ZnHj[UBtd2OjbHn6ZZRqd25?	MlTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7Nk[3PFkoRjF7OU[2O\|g6RC:jPh?=
CFBE41o-	MVnLbY5ie2ViQYPzZZk>	MmLVNUDPxE1?	Mk[zOUBl[Xm\|	MWrEUXNQ	M2n1W2lvcGmkaYTpc44hd2ZiSFTBR\|ch[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gd5Ri[mmuaYrheIlwdiCxZjDG[IVtfGF3MEigR2ZVWiCycn;0[Ylv	Mlr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7Nk[3PFkoRjF7OU[2O\|g6RC:jPh?=
CFBE41o-	MkjVT4lv[XOnIFHzd4F6	NFy1cYMyKM7:TR?=	M4jRWlI1KGh?	M2C3dmROW09?	MXXJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4hfHKjZn\pZ4tqdmd?	M2DlO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[2O\|g6Lz5zOUm2Olc5QTxxYU6=
CFBE41o-	NYTKdIdoU2mwYYPlJGF{e2G7	NYnITVNHPSEQvF2=	NGniNGMzPCCq	MojtSG1UVw>?	NFz2bHNKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJJifGVib3[gcYF1fXKjdHnvckBw\iCFRmTSJJBzd3SnaX6geI8hcXS\|IHfsfYNw\m:{bR?=	NH2yOZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2Olc5QSd-MUm5OlY4QDl:L3G+
CFBE41o-	Mm\LT4lv[XOnIFHzd4F6	NUTsWJA3PSEQvF2=	M2jHWFI1KGh?	NXTVfVNJTE2VTx?=	M3\DPGlvcGmkaYTpc44hd2ZiSFTBR\|ch[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gd5Ri[mmuaYT5JI9nKE[mZXz0ZVUxQCCFRmTSJJBzd3SnaX6=	M2e0NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[2O\|g6Lz5zOUm2Olc5QTxxYU6=
CFBE41o-	NYr5[otuU2mwYYPlJGF{e2G7	MoXuOUDPxE1?	MnfKNlQhcA>?	MUTEUXNQ	NGrldZdKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHPvdpJm[3Srb36gc4YhdXW2YX70JGZl\Wy2YUWwPEBETlSUIITyZYZncWOtaX7nJJRwKGOnbHygd5Vz\mGlZTDhd{BodHmlb3\vdo0>	M1m2XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[2O\|g6Lz5zOUm2Olc5QTxxYU6=
Primary bronchial epithelial cell	MmPHT4lv[XOnIFHzd4F6	MVK1JO69VQ>?	MV[yOEBp	NEL1[JJFVVOR	MmXpTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDteZRidnRiRnTlcJRiPTB6IFPGWHIheHKxdHXpckBieGmlYXygd5Vz\mGlZTDsc4NidGm8YYTpc44>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTl4Nke4PUc,OTl7Nk[3PFk9N2F-
Primary bronchial epithelial cell	NVHTWXkyU2mwYYPlJGF{e2G7	NHTNbHcyKM7:TR?=	MYe5OkBp	NWTndJJtTE2VTx?=	MW\Jcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIPoc5J1KGOrcnP1bZQh[3W{cnXueJM>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTl4Nke4PUc,OTl7Nk[3PFk9N2F-
BxPC3	Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M13BeVczKGh?		NILOR5pKSzVyPUKuO{DPxE1?	NIH1[\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
CAL27	NXSyXpFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M17PTlczKGh?		NYjIbph7UUN3ME2zMlczKM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
Capan1	NGPscHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYjNXZM{PzJiaB?=		MmXUTWM2OD15LkOg{txO	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
HCC827	Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVTJSnJoPzJiaB?=		MUjJR\|UxRTFwODFOwG0>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
LNCAP	NXv2WVhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWnyOG5[PzJiaB?=		MYXJR\|UxRTBwNUig{txO	MonNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
NCI-H2122	M3LKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWG3NkBp		NVvxSoNJUUN3ME23MlUh\|ryP	MoGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
NCI-H358	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1TEUVczKGh?		MX7JR\|UxRTJwNTFOwG0>	M1rvS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzO\|c5Lz5{MEG0N\|c4QDxxYU6=
SCC15	NEnhfVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoHqO\|IhcA>?		NYPsUIp{UUN3ME2yMlQ6KM7:TR?=	MmXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
SCC25	NUf5c5psT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmXKO\|IhcA>?		Ml7WTWM2OD1zLkmzJO69VQ>?	NWHDVoVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM4PzhpPkKwNVQ{Pzd6PD;hQi=>
SKHEP1	M4faOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUO3NkBp		M4C5d2lEPTB;Mz60OkDPxE1?	MlLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
BJ	MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fsSFExOCEQvF2=	Ml3zOFghcA>?	NXriXm5ITE2VTx?=	M2TmNGdzd3e2aDDpcohq[mm2aX;uJIF1KDBwMEWgeI8hOTByIIXN	NWr2RpljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM5PDBpPkKwNVQ{QDRyPD;hQi=>
MUF	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDwRmN6OTByIN88US=>	NFKyOmo1QCCq	MoK2SG1UVw>?	MnLoS5Jwf3SqIHnubIljcXSrb36gZZQhOC5yNTD0c{AyODBidV2=	MoTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO4OFAoRjJyMUSzPFQxRC:jPh?=
Caco-2	M1v3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGj3eYwyODBizszN	NVvXUVJmPDiq	MUfEUXNQ	MmKwTWM2OD16LkGg{txO	NIrXfWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|g1OCd-MkCxOFM5PDB:L3G+
Caco-2	MVvLbY5ie2ViQYPzZZk>	M3zkU\|Uh\|ryP	MUW0JIg>	M17BemROW09?	NXj6XJhYUW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQhcGm\|dH;u[UBi[2W2eXzheIlwdiCLQ{WwJI9nKDBwMEO3JO69VQ>?	M4nOUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzPFQxLz5{MEG0N\|g1ODxxYU6=
Caco-2	M2nSUWtqdmG\|ZTDBd5NigQ>?	NGDUZVkxNjNzNjDuUUB1dyB\|MT62JO69VQ>?	NXvLZph[PCCq	NVvnNZk1TE2VTx?=	Mkj5SZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUNzIIfpeIghUUN3MDDv[kAxNjFzOTFOwG0>	NUfRZmMyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM5PDBpPkKwNVQ{QDRyPD;hQi=>
Caco-2	M2G2eWtqdmG\|ZTDBd5NigQ>?	MVKwMlMyPiCwTTD0c{A{OS54IN88US=>	NFPDO5c1KGh?	MYXEUXNQ	NIXTN4NGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Oge4l1cCCLQ{WwJI9nKDBwMUS3JO69VQ>?	NXvIS4ZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM5PDBpPkKwNVQ{QDRyPD;hQi=>
Caco-2	M17wOGtqdmG\|ZTDBd5NigQ>?	Mn;BOk4{OiCwTTD0c{A3OzJizszN	NX76XYtnPCCq	MlzxSG1UVw>?	NWrjbGptTXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO1JJdqfGhiSVO1NEBw\iBzMj62JO69VQ>?	M1XidlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzPFQxLz5{MEG0N\|g1ODxxYU6=
Caco-2	NYC2V3ZzU2mwYYPlJGF{e2G7	M4e1d\|YvOzJibl2geI8hPjN{IN88US=>	M4fJZ\|QhcA>?	M4\TRmROW09?	NIDjW5pGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{ege4l1cCCLQ{WwJI9nKDRzIN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{i0NEc,OjBzNEO4OFA9N2F-
Caco-2	NXj2SJN3U2mwYYPlJGF{e2G7	NWjMdVREOC5\|MU[gcm0hfG9iM{GuOkDPxE1?	NF30cnE1KGh?	NFvpZVhFVVOR	MUPFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzZ?	NYXCRW4{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM5PDBpPkKwNVQ{QDRyPD;hQi=>
HepG2	NEXaU5hMcW6jc3WgRZN{[Xl?	NW\HV2FUPSEQvF2=	NEj6VWE3cA>?	M3ezUGROW09?	NF3hZo9KdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBpcXO2b37lJIFk\XS7bHH0bY9v	NHOxWZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|g1OCd-MkCxOFM5PDB:L3G+
HepG2	MYTLbY5ie2ViQYPzZZk>	NG[xdG02KM7:TR?=	NFPnOWQ3cA>?	NYHWb497TE2VTx?=	Mn[3TY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgbIl{fG:wZTDofZBmemGlZYT5cIF1cW:w	M2[2R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzPFQxLz5{MEG0N\|g1ODxxYU6=
HepG2	MnyxT4lv[XOnIFHzd4F6	Mnu0OUDPxE1?	MWW2bC=>	NW\Qdmo3TE2VTx?=	Ml;6TY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgZYxxcGFvdIXieYxqdiCjY3X0fYxifGmxbh?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{i0NEc,OjBzNEO4OFA9N2F-
HepG2	NWrIToNCU2mwYYPlJGF{e2G7	NHrF[Go2KM7:TR?=	MXi2bC=>	M3;HUmROW09?	NFj1RY1KdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBJOy:KNDDobZN1d26nIHHj[ZR6dGG2aX;u	MlXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO4OFAoRjJyMUSzPFQxRC:jPh?=
COLO205	M371WWtqdmG\|ZTDBd5NigQ>?	NV3icHNPOTBizszN	MYeyOEBp	M2X0UGROW09?	NUO5RZVJUW6qaXLpeIlwdiCxZjDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm\|dH;u[UBJOyCjY3X0fYxifGmxbjD3bZRpKEmFNUCgc4YhOi5{IN88US=>	NH3CSog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES1NVM4QCd-MkC0OVE{Pzh:L3G+
SCC4	M1;iO2tqdmG\|ZTDBd5NigQ>?	M4rnTFEh\|ryP	MV6yOIg>		M{D2ZWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjD0eYJ2dGmwIHHj[ZR6dGG2aX;u	NFnifIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES1NlIzPSd-MkC0OVIzOjV:L3G+
SCC4	MmThT4lv[XOnIFHzd4F6	M3j6blEh\|ryP	M2DtSFI1cA>?		NH36R3RKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDhZ4V1gWyjdHnvci=>	NHrxTo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES1NlIzPSd-MkC0OVIzOjV:L3G+
SCC4	NYO5[2ZNTnWwY4Tpc44hSXO\|YYm=	NXfCcpJbOSEQvF2=	MXK1JI1qdg>?		NEjVcIRC\2:waYP0JIFkfGm4aYT5JIF1KF[GUjDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiQ2nQNlQh\2WwZTDlfJBz\XO\|aX;u	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR3MkKyOUc,OjB2NUKyNlU9N2F-
NB4	M2rjW2Z2dmO2aX;uJGF{e2G7	Ml\mOUDPxE1?	NXrocVhUOjRiaB?=	NXHSTVZkTE2VTx?=	NHL4Z5VE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4N2dXWuYYTpc44h[XRicILlMWcyKHCqYYPl	M3PTXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEmxOFQxLz5{MES5NVQ1ODxxYU6=
NB4	NHrjTVJMcW6jc3WgRZN{[Xl?	NXG4b\|JoPSEQvF2=	MUCyOEBp	MnHzSG1UVw>?	NVzmfpBrUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIFk\XS7bHH0[UB1fWK3bHnuJIxmfmWu	M{[zeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEmxOFQxLz5{MES5NVQ1ODxxYU6=
NB4	NEnpNmdHfW6ldHnvckBCe3OjeR?=	NG\G[XE2KM7:TR?=	NVLP[FJkOjRiaB?=	M4f4VmROW09?	M2XtXWlv\HWldHnvckBw\iCyMkHXRWYyN0OLUEGg[ZhxemW\|c3nvci=>	M4HUVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEmxOFQxLz5{MES5NVQ1ODxxYU6=
NB4	NIXy[opMcW6jc3WgRZN{[Xl?	NVTWXlBtPSEQvF2=	MXWyOEBp	MYHEUXNQ	M3:zN2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFizJIFk\XS7bHH0bY9v	MkLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2OUG0OFAoRjJyNEmxOFQxRC:jPh?=
NUGC3	Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInWdlJIUTVyPUKuPVQh\|ryP	MkWzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6NUC5O\|EoRjJyOEWwPVcyRC:jPh?=
A549	MVvGeY5kfGmxbjDBd5NigQ>?	Mn7COUDPxE1?	NYHGeWtxOyCq	Mn\4SG1UVw>?	NH7rVphKdmS3Y4Tpc44hd2ZiYYX0c5Bp[We7IHnuJIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iTFOzTWk>	NVWzRlVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4OVUzODhpPkKwPFU2OjB6PD;hQi=>
HUT78	NGPvbIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXK3NkBp	M3rPTmROW09?	M3HJcGdKPTB;MD6zJO69VQ>?	NUW3OGUyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFQzODhpPkKwPFg1OjB6PD;hQi=>
U937	NV3FZ2xCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX[3NkBp	NXSwbIhJTE2VTx?=	NVHJUGp6T0l3ME2wMlM6KM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6NEKwPEc,OjB6OESyNFg9N2F-
A431	MmGwR5l1d3SxeHnjJGF{e2G7		Mn3QO\|IhcA>?		MV;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJI93\XKneIDy[ZN{cW6pIFXHSnIhf2m2aDDJR\|UxKG:oIESuNkDPxE1?	M1i2flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEiwOlI6Lz5{MUC4NFYzQTxxYU6=
A549	NF3kU5BEgXSxdH;4bYMhSXO\|YYm=		NXvmb5c1PzJiaB?=		MoLuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISGFEKHerdHigTWM2OCCxZjCxMlgh\|ryP	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6ME[yPUc,OjFyOEC2Nlk9N2F-
CAL27	MUXDfZRwfG:6aXOgRZN{[Xl?		M3q5OlczKGh?		NUf3NJJuS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0GOMkegZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjD3bZRpKEmFNUCgc4YhOy5{IN88US=>	NF\Rd5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC4NFYzQSd-MkGwPFA3Ojl:L3G+
HeLa	MlvyR5l1d3SxeHnjJGF{e2G7		M1vM[VczKGh?		NWCxd4ZsS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BJTEGFIIfpeIghUUN3MDDv[kAyNjVizszN	M{TVNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEiwOlI6Lz5{MUC4NFYzQTxxYU6=
Sf21	M{XwW2tqdmG\|ZTDBd5NigQ>?		MlXwN{Bp		MnvCTY5pcWKrdHnvckBw\iCIbHHnJJRi\2enZDDoeY1idiC{ZXPvcYJqdmGwdDDISGFEQCCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEvOiEQvF2=	Mn7WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyOEC2NlkoRjJzMEiwOlI6RC:jPh?=
SKBR3	M{CxT2N6fG:2b4jpZ{BCe3OjeR?=		MWm3NkBp		M1n1cWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMSlJ\|IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGhGWjJid3n0bEBKSzVyIH;mJFIvPiEQvF2=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6ME[yPUc,OjFyOEC2Nlk9N2F-
SKOV3	M1:2XmN6fG:2b4jpZ{BCe3OjeR?=		NFX4RYk4OiCq		Mn3LR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMhd3[ncnX4dJJme3OrbnegTGVTOiC5aYToJGlEPTBib3[gNk4zKM7:TR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6ME[yPUc,OjFyOEC2Nlk9N2F-
COR-L23	MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITocnoyOCEQvF2=	NX;NN2lkPzJiaB?=	MWXEUXNQ	M2TXNWdKPTB;MT6xJO69VQ>?	NUnoZ4M2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwPFA3PDdpPkKxNFgxPjR5PD;hQi=>
DU145	NFTGRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\1NVAh\|ryP	MmraO\|IhcA>?	MWLEUXNQ	MofGS2k2OD1zLkC1JO69VQ>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6ME[0O{c,OjFyOEC2OFc9N2F-
LoVo	M2LmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHKNIhjOTBizszN	MXe3NkBp	MV3EUXNQ	NHezUWFIUTVyPUGuO{DPxE1?	NF[4Uno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC4NFY1Pyd-MkGwPFA3PDd:L3G+
MCR5-SV2	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rPOVExKM7:TR?=	NHnze3E4OiCq	M4LyNGROW09?	NYT4cJlWT0l3ME2yMlEh\|ryP	NGTIUFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC4NFY1Pyd-MkGwPFA3PDd:L3G+
HCT116	NIfjZXNMcW6jc3WgRZN{[Xl?	MXuzNEDPxE1?	NXzxVmhQOzBiaB?=	NF34dYhFVVOR	MlnlTY5pcWKrdHnvckBw\iCKRFHDOkBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gZYxxcGFvdIXieYxqdiCjY3X0fYxifGmxbh?=	MlvyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyOEC2OFcoRjJzMEiwOlQ4RC:jPh?=
HCT116	MmLMT4lv[XOnIFHzd4F6	M1[5UVMxKM7:TR?=	MmnvN\|AhcA>?	Mn\WSG1UVw>?	NEnvSpFKdmirYnn0bY9vKG:oIFjERWMyKGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBpcXO2b37lJGg{UzliYXPleJlt[XSrb36=	NVrvN2VDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwPFA3PDdpPkKxNFgxPjR5PD;hQi=>
U937	MoPRT4lv[XOnIFHzd4F6	NVzyR4U4PSEQvF2=	M33FdVI1KGh?	M2naZmROW09?	NVzsc2NwUW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{m=	M2\WblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkmyOFkzLz5{MUK5NlQ6OjxxYU6=
U937	M37BbWtqdmG\|ZTDBd5NigQ>?	MYK1JO69VQ>?	MUeyOEBp	MknwSG1UVw>?	NXv0SmFFUW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{G4	NHrPO4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUK5NlQ6Oid-MkGyPVI1QTJ:L3G+
U937	MV\LbY5ie2ViQYPzZZk>	NXrQ[\|E{PSEQvF2=	MnfyNlQhcA>?	MlLTSG1UVw>?	MVvJcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO\|ZYPz[YQh[XNiaX7jdoVie2Vib3[gdIFvNWGlZYT5cIF1\WRiaHnzeI9v\SCKNDDs[ZZmdA>?	MmGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{OUK0PVIoRjJzMkmyOFkzRC:jPh?=
U937	M3y3XGtqdmG\|ZTDBd5NigQ>?	MmnEOUDPxE1?	NGKw[VEyPSCvaX6=	Moi3SG1UVw>?	MnHOTY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6\|ZnXyZZNmKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIH;mJIhqe3SxbnWgTFMh[WOndInsZZRqd25ibHX2[Yw>	NWP4Z\|J[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyPVI1QTJpPkKxNlkzPDl{PD;hQi=>
A2780	M3vhVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWDzS4dGQTZiaB?=	NELOfZRFVVOR	MX3JR\|UxRTFwNkKg{txO	M4XOflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkO0OFMxLz5{MU[zOFQ{ODxxYU6=
COLO205	NGTjU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV[5OkBp	NEDoSFVFVVOR	MnP6TWM2OD1{LkGyJO69VQ>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ\|NESzNEc,OjF4M{S0N\|A9N2F-
Hep3B	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWnOOJBQPDhiaB?=	MkHNSG1UVw>?	MoDiS2k2OD1zLkKxJO69VQ>?	NY\tfWxuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NVIyPDZpPkKxO\|EzOTR4PD;hQi=>
GM11272	MoqwSpVv[3Srb36gRZN{[Xl?	MYGxNFAhdk1?	NUfUXlg2PzJiaB?=	NHTUS\|ZFVVOR	NVy0TVV2WmWjY4TpeoF1cW:wIH;mJG1mS3B{IH31eIFvfCCneIDy[ZN{cW:wIHH0JFExKHSxIEGwNEBvVQ>?	MoXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6NEC3NVYoRjJzOESwO\|E3RC:jPh?=
CFBE41o	M3HLVmtqdmG\|ZTDBd5NigQ>?	MmC1OUDPxE1?		MmLpSG1UVw>?	M{C3dGRwf25icnXneYxifGmxbjDv[kBJTEGFNzDheEAxNjJidH:gOUB2VQ>?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl6NEm1PEc,OjF7OES5OVg9N2F-
CFBE41o	MXfGeY5kfGmxbjDBd5NigQ>?	MofmNUDPxE1?	MWKyOEBp	MXPEUXNQ	NGW5XVNT\XO2b4LheIlwdiCxZjDDSnRTKGSnbIThSlUxQCCvdYThcpQhfHKjZn\pZ4tqdmdidH:gZ4VtdCC\|dYLmZYNmKGG\|IHfsfYNw\m:{bYO=	MoPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7OES5OVgoRjJzOUi0PVU5RC:jPh?=
DU145	Ml;HT4lv[XOnIFHzd4F6	NYHOXGFROi53IN88US=>	M{nT[FI1KGh?	MUHEUXNQ	MkjWTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KHWycnXneYxifGmxbjDv[kBxOjG5YX[xJJBzd3SnaX6g[ZhxemW\|c3nvci=>	NF7BXIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK2NFE3Pid-MkKyOlAyPjZ:L3G+
DU145	MYXLbY5ie2ViQYPzZZk>	MXy1JO69VQ>?	M{jPOFI1KGh?	MXrEUXNQ	NGrmdnlKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaHnzeI9v\SCKNDDhZ4V1gWyjdHnvci=>	M{SycFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[wNVY3Lz5{MkK2NFE3PjxxYU6=
DU145	MmXRT4lv[XOnIFHzd4F6	MUm1JO69VQ>?	MlLpNlQhcA>?	NYPuR\|J[TE2VTx?=	MYDJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcGm\|dH;u[UBJOyCqeYDldoFk\XS7bHH0bY9v	NHn5dHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK2NFE3Pid-MkKyOlAyPjZ:L3G+
786-0	NGT5RlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3FXGI3NjJizszN	NGrTS5I4OiCq	MV7EUXNQ	MlvUS2k2OD1\|LkKg{txO	M2LtVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
A498	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzEOk4zKM7:TR?=	NIL0OlM4OiCq	M3S1SGROW09?	NUnZ[pJyT0l3ME2xMlYh\|ryP	M1LueFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
A549/ATCC	NU\ifY45T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TRd\|YvOiEQvF2=	MUm3NkBp	M2jFfGROW09?	MnGxS2k2OD1zLk[g{txO	MmfsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
ACHN	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XJ[VYvOiEQvF2=	Mn;6O\|IhcA>?	NYX2Z3RoTE2VTx?=	MYfHTVUxRTFwMzFOwG0>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
BT549	MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fId\|YvOiEQvF2=	MkPHO\|IhcA>?	NHGzc5VFVVOR	M1PxV2dKPTB;MT6zJO69VQ>?	NUHyfIJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
EKVX	Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWK2MlIh\|ryP	NES0b244OiCq	M2rYfWROW09?	MmHJS2k2OD1zLkOg{txO	MmfrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
HCT15	M2HybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rtUVYvOiEQvF2=	MXq3NkBp	MmTzSG1UVw>?	NXXz[\|ZbT0l3ME2yMlUh\|ryP	M2LEdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
HOP92	NWXzVXZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\lSVYvOiEQvF2=	M3[4bVczKGh?	NXf3NoVYTE2VTx?=	NX;qVop4T0l3ME20JO69VQ>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
IGROV1	NGXmU\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjyOk4zKM7:TR?=	NX;oWJRJPzJiaB?=	NVi0TZk6TE2VTx?=	Mm\iS2k2OD1zLkOg{txO	MnTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
LOXIMVI	NUmwOlNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTofG1rPi5{IN88US=>	NV[weoNJPzJiaB?=	M164TGROW09?	M1jXbmdKPTB;MTFOwG0>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
M14	NHjU[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYO2MlIh\|ryP	NX;UNpU{PzJiaB?=	M1\2S2ROW09?	NXfnOHd2T0l3ME2xMlMh\|ryP	NFHqclk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
MALME-3M	NEXMfHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3yzfVYvOiEQvF2=	M4LOXFczKGh?	M3:5eGROW09?	NF:zSJdIUTVyPUCuN\|Ih\|ryP	NWPUbJpiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
MCF10A	MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkP6Ok4zKM7:TR?=	MlHpOFghcA>?	MVXEUXNQ	NEDyRXBIUTVyPUmuOkDPxE1?	NHW4UWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
MDA-MB-435	MojoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\M[FYvOiEQvF2=	M2n2blczKGh?	NYPCU2RTTE2VTx?=	NXHIb2ZrT0l3ME2wMlUh\|ryP	NVTudXBHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
MDA-MB-468	NWLmOW1QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\JOk4zKM7:TR?=	M4XqWlczKGh?	NI\UXIhFVVOR	M3SyTGdKPTB;MD62N{DPxE1?	NWr2b\|FvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
MOLT4	NHizfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUC2MlIh\|ryP	NX73b\|h5PzJiaB?=	MX\EUXNQ	MXnHTVUxRTBwNDFOwG0>	NYTyfnJGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
NCI-ADR-RES	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PMb\|YvOiEQvF2=	MV23NkBp	MVvEUXNQ	M4XvfGdKPTB;MD6xOkDPxE1?	M4nqZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
NCI-H23	M3;6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkW4Ok4zKM7:TR?=	NEnwXm44OiCq	MYXEUXNQ	NH7XXopIUTVyPUGg{txO	NUXaVpJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
NCI-H322M	NYTzfVVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXi2MlIh\|ryP	MnXjO\|IhcA>?	MnPKSG1UVw>?	MkDGS2k2OD1yLke5JO69VQ>?	M1K5NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
NCI-H460	NGHjWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfCe5g3NjJizszN	Mk\rO\|IhcA>?	M3S0cGROW09?	MYLHTVUxRTBwN{mg{txO	NUDwcoluRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
NCI-H522	M1XR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\yO4VPPi5{IN88US=>	Mny3O\|IhcA>?	M2\0NGROW09?	MoHMS2k2OD1yLkWg{txO	NGTMbGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
OVCAR3	NXvyc\|J6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfabldLPi5{IN88US=>	NE\pWYY4OiCq	NXTIVVZnTE2VTx?=	NF3SbotIUTVyPUGuN{DPxE1?	NFiwTo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
OVCAR4	NEn6SnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4O0PVYvOiEQvF2=	Mn7QO\|IhcA>?	NIDYSmRFVVOR	MWnHTVUxRTRizszN	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
OVCAR5	M1O4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUW2MlIh\|ryP	M1XXXVczKGh?	MmfQSG1UVw>?	M2rNTmdKPTB;MD63PUDPxE1?	NYnTTZBJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
OVCAR8	NIrzV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7rWYI3NjJizszN	M{DoeVczKGh?	NHjSWXlFVVOR	MmOyS2k2OD1yLkWg{txO	NYW1dGZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
RXF393	NGPpUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHQOk4zKM7:TR?=	MlvxO\|IhcA>?	NF74VnZFVVOR	NEPiOZBIUTVyPUGuN{DPxE1?	MnWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
SF268	NX3VXIxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HEUFYvOiEQvF2=	MVi3NkBp	NFXtTVdFVVOR	MXPHTVUxRTFwNjFOwG0>	NVSyfJZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
SF295	M3ewe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\LclYvOiEQvF2=	M1\IRVczKGh?	NGDjfHZFVVOR	M4Lu[WdKPTB;MT62JO69VQ>?	NV;rcpFrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
SF539	NFK5XpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rCPVYvOiEQvF2=	NWizeYhNPzJiaB?=	MVvEUXNQ	MV\HTVUxRTJizszN	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
SK-MEL-2	NEW1UVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYS2MlIh\|ryP	MXi3NkBp	Mnj1SG1UVw>?	Mkn5S2k2OD1zLkOg{txO	NFnjfGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
SK-MEL-28	NVTBTGNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWKxXJRoPi5{IN88US=>	NHPFXm84OiCq	NHLBUWJFVVOR	NXi4eZNqT0l3ME2xJO69VQ>?	NInVeFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
SK-MEL-5	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rTSVYvOiEQvF2=	M3:wbVczKGh?	Mo\JSG1UVw>?	NIrofXhIUTVyPUCuOlMh\|ryP	NWfj[pljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
SKOV3	MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYi2MlIh\|ryP	M2jnNFczKGh?	M{DtTGROW09?	MVrHTVUxRTFizszN	NEnTc\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
SN12C	M1LYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPQOk4zKM7:TR?=	NXq0SHpMPzJiaB?=	NH;tb4xFVVOR	M2fSU2dKPTB;MjFOwG0>	MofRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
SNB19	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HP[\|YvOiEQvF2=	M3TlTFczKGh?	MnrVSG1UVw>?	NG\ScW1IUTVyPUCuOlMh\|ryP	MlziQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
SNB75	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHufHB3Pi5{IN88US=>	M3LydFczKGh?	MX7EUXNQ	M{PDfmdKPTB;MD63PUDPxE1?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|NU[2PUc,OjJ2M{W2Olk9N2F-
SR	NHfQR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHFRmQ3NjJizszN	MojnO\|IhcA>?	NYK3ZWhtTE2VTx?=	M3rleGdKPTB;MD60JO69VQ>?	NWjP[XJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
T47D	MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV:2MlIh\|ryP	NXO0fmFEPzJiaB?=	MnHwSG1UVw>?	MUXHTVUxRTBwNTFOwG0>	MkG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{W2OlkoRjJ{NEO1OlY6RC:jPh?=
TK10	M{Cycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjqSHU3NjJizszN	NV[5XZpOPzJiaB?=	Mlz6SG1UVw>?	NXnLU2RHT0l3ME2wMlY{KM7:TR?=	M2\6blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
UACC257	MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnDUWQ3NjJizszN	Ml3UO\|IhcA>?	Mn;VSG1UVw>?	M4HORWdKPTB;MD61JO69VQ>?	M{PTVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEO1OlY6Lz5{MkSzOVY3QTxxYU6=
UACC62	NFuzPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\YOk4zKM7:TR?=	M2TMTVczKGh?	NYnaT3BOTE2VTx?=	M365[GdKPTB;MD60JO69VQ>?	NULZN2dPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0N\|U3PjlpPkKyOFM2PjZ7PD;hQi=>
UO31	M1SzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnKxOk4zKM7:TR?=	NIP3bGo4OiCq	MlPwSG1UVw>?	M1fQfmdKPTB;MD61JO69VQ>?	NH\iRWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSzOVY3QSd-MkK0N\|U3Pjl:L3G+
Hep3B	Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnntOFghcA>?	NH\NW3hFVVOR	M1jhbmdKPTB;MD62PUDPxE1?	MmPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2M{m4OlMoRjJ{NEO5PFY{RC:jPh?=
BE(2)-C	M{e2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX63NkBp	NEf5bnNFVVOR	M37RdGlEPzB;MjFOwG0>	NWjaWXVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5N\|I{OTZpPkKyPVMzOzF4PD;hQi=>
Bel7402	NXuwUGdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkHtO\|IhcA>?	NIf5dlVFVVOR	NVW1OGJ3T0l7ME2xO{DPxE1?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4MUO3Okc,OjNyNkGzO\|Y9N2F-
Bel7404	NWm3N3BqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmjnO\|IhcA>?	NV6zVldGTE2VTx?=	Mmn6S2k6OD1zODFOwG0>	NVzjdpZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlE{PzZpPkKzNFYyOzd4PD;hQi=>
BGC823	NX36V5hvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{DBbFczKGh?	M2LVWmROW09?	NXLNfmJCT0l7ME23MlUh\|ryP	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4MUO3Okc,OjNyNkGzO\|Y9N2F-
MGC803	NYDZeohkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MY[3NkBp	MXHEUXNQ	NYnaToVmT0l7ME2xNE45KM7:TR?=	MkjPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkGzO\|YoRjJ\|ME[xN\|c3RC:jPh?=
SGC7901	M{jYXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkC2O\|IhcA>?	NVfQdGp[TE2VTx?=	NWDCdYNDT0l7ME25MlQh\|ryP	MnrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkGzO\|YoRjJ\|ME[xN\|c3RC:jPh?=
SKHEP1	NEDlOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUK3NkBp	MV7EUXNQ	NVSxSJR1T0l7ME2xO{DPxE1?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4MUO3Okc,OjNyNkGzO\|Y9N2F-
SMMC7721	MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml3oO\|IhcA>?	M{DnOWROW09?	MWfHTVkxRTJyIN88US=>	M2HDPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[xN\|c3Lz5{M{C2NVM4PjxxYU6=
NUGC3	M{L0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvzNWgyOCEQvF2=			MnLPS2k:Oi57NDFOwG0>	NVy2OYJ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOlM{OzJpPkKzNVY{OzN{PD;hQi=>
A2780 CisR	MojQT4lv[XOnIFHzd4F6		NInpNFgyQCCq		M1\6U2lvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD60OEDPxE1?	MkO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUK2NFMoRjJ\|MkWyOlA{RC:jPh?=
CAL27 sens	MnjDT4lv[XOnIFHzd4F6		Mn3NNVghcA>?		M2PidGlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD6zOkDPxE1?	NHKzdJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1NlYxOyd-MkOyOVI3ODN:L3G+
CAL27 CisR	MV3LbY5ie2ViQYPzZZk>		M3vzWlE5KGh?		MYjJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNkGg{txO	NHHtXGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1NlYxOyd-MkOyOVI3ODN:L3G+
KYSE-510 CisR	M{PVVmtqdmG\|ZTDBd5NigQ>?		M1XJRlE5KGh?		MV\Jcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNUmg{txO	M{LHZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkWyOlA{Lz5{M{K1NlYxOzxxYU6=
KYSE-510 sens	NVjRWplTU2mwYYPlJGF{e2G7		NX[1bGxrOThiaB?=		NGjsb5NKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuO{DPxE1?	NWXRVYRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOVI3ODNpPkKzNlUzPjB\|PD;hQi=>
MDA-MB-231 sens	NHXPe2tMcW6jc3WgRZN{[Xl?		M1L0NlE5KGh?		NGniSlNKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOlEh\|ryP	NHnCNI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1NlYxOyd-MkOyOVI3ODN:L3G+
MDA-MB-231 CisR	M1zlcmtqdmG\|ZTDBd5NigQ>?		MX6xPEBp		MWLJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNkGg{txO	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ3Mk[wN{c,OjN{NUK2NFM9N2F-
ES2	M1z5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUm0PEBp	NVy4WXhsTE2VTx?=	MlK5TWM2OD1zMj63JO69VQ>?	NEDBTVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5N\|Q1QSd-MkO0PVM1PDl:L3G+
MDA-MB-231	M1jzcGtqdmG\|ZTDBd5NigQ>?	MlWxNVAh\|ryP	MVGzNEBucW5?	M3;2V2ROW09?	NEXEdJJKdmirYnn0bY9vKG:oIFjERWMz[Q>?	M3nnelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEmzOFQ6Lz5{M{S5N\|Q1QTxxYU6=
MDA-MB-231	NXrVWo1qU2mwYYPlJGF{e2G7	M{H0fFEh\|ryP	NHn6SWUzPCCq	NVr0WYlETE2VTx?=	NFvB[oxKdmirYnn0bY9vKG:oIFjERWM3KGG\|c3Xzd4VlKGG\|IHHj[ZR6dGG2aX;uJIxmfmWuczDv[kB1fWK3bHnu	NV;ab2FIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVM1PDlpPkKzOFk{PDR7PD;hQi=>
HS68	MU\DfZRwfG:6aXOgRZN{[Xl?	M3POOFExKM7:TR?=	NXWxc3JXPzJiaB?=	M3HneGROW09?	NHXGSY9KSzVyPUSuOkDPxE1?	NGrwSVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W3NFU1Oid-MkO1O\|A2PDJ:L3G+
MEF	M{G5OGN6fG:2b4jpZ{BCe3OjeR?=	MX[xNEDPxE1?	NU\NUJJCPzJiaB?=	NGrlXXFFVVOR	MUDJR\|UxRTRwNDFOwG0>	NV7xU3d[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1O\|A2PDJpPkKzOVcxPTR{PD;hQi=>
BGC823	M2PtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVu5SoRuTE2VTx?=	M{HiVWdKPTB;Mz6wPUDPxE1?	NHXSe2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[wNVcxPid-MkO2NFE4ODZ:L3G+
High5	NVLJRZJ{U2mwYYPlJGF{e2G7		MUGyOEBp		NHS2fHNKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWM3KHerdHigTWM2OCCxZjCwMlA6KM7:TR?=	MnK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MEK1NlMoRjJ\|NkCyOVI{RC:jPh?=
High5	NXPiOY9tU2mwYYPlJGF{e2G7		NFfyUnkzPCCq		MUnJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOxJJdqfGhiSVO1NEBw\iByLkGyJO69VQ>?	M3zKXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkCyOVI{Lz5{M{[wNlUzOzxxYU6=
High5	M3\LOGtqdmG\|ZTDBd5NigQ>?		MYeyOEBp		MkC1TY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDN{B4cXSqIFnDOVAhd2ZiMD6xO{DPxE1?	NIDBb2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[wNlUzOyd-MkO2NFI2OjN:L3G+
A549	M1jYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUDFPJduTE2VTx?=	NIrpSotKSzVyPUGuNFc6KM7:TR?=	M2PEVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkS0NlExLz5{M{[0OFIyODxxYU6=
HCT116	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXrEUXNQ	NX\QVIh6UUN3ME2wMlc2PyEQvF2=	NVyy[WdIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OFQzOTBpPkKzOlQ1OjFyPD;hQi=>
K562	NWjyXGNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXL0bWc{TE2VTx?=	NGSwTXBKSzVyPUCuOlQ2KM7:TR?=	Ml3IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4NESyNVAoRjJ\|NkS0NlExRC:jPh?=
GBC-SD	NW\ONIE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4m3T\|Uh\|ryP	Mn3KO\|IhcA>?	NVLQSGlqTE2VTx?=	NGizWmFKSzVyPUG0Mlgh\|ryP	NFP2Omw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewO\|I3OCd-MkO3NFczPjB:L3G+
HGC27	M3TQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13GSVUh\|ryP	NGDRNVk4OiCq	MnzOSG1UVw>?	NUj2cXl2UUN3ME21MlQh\|ryP	NYHpc\|lnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NFczPjBpPkKzO\|A4OjZyPD;hQi=>
HL60	MX7LbY5ie2ViQYPzZZk>	M1\3OVUh\|ryP	MV:yOEBp	NGDjRZNFVVOR	NFX5c2FKdmirYnn0bY9vKG:oIFjERWM>	NFHlRmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewO\|I3OCd-MkO3NFczPjB:L3G+
Vero	Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGrvPZQ4OiCq	M3zLTGROW09?	NV3vWIw{UUN3ME2wMlkh\|ryP	M1zGW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{i2OFUzLz5{M{e4OlQ2OjxxYU6=
NCI60	MVvDfZRwfG:6aXOgRZN{[Xl?		NEnpOWw1QCCq	NUjuOHg1TE2VTx?=	M3vjOWdKRTBwNUOg{txO	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzNUOyO{c,OjRyMUWzNlc9N2F-
SW620	MXrDfZRwfG:6aXOgRZN{[Xl?		M{XGXVQ5KGh?	MkjESG1UVw>?	MX;HTV0xNjV2IN88US=>	M2K0dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG1N\|I4Lz5{NECxOVMzPzxxYU6=
U251	NWjnepNMS3m2b4TvfIlkKEG\|c3H5		MmXtOFghcA>?	MnfBSG1UVw>?	MYDHTV0yNjV\|IN88US=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzNUOyO{c,OjRyMUWzNlc9N2F-
KM12	NV\PfXZDS3m2b4TvfIlkKEG\|c3H5		M4rLSFQ5KGh?	NEjxcohFVVOR	MljkS2k:OS56ODFOwG0>	NGHXN2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxOVMzPyd-MkSwNVU{Ojd:L3G+
Hs578T	NXPBbo1JS3m2b4TvfIlkKEG\|c3H5		MVS0PEBp	MVjEUXNQ	NVzie4p1T0l;ND64N{DPxE1?	NUPsUXpNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVU{OjdpPkK0NFE2OzJ5PD;hQi=>
MDA-MB-231	NHy4bFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1;EPVQ5KGh?		MojwTWM2OD1yLkG2JO69VQ>?	NXnUbHZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVUxOTZpPkK0NFk2ODF4PD;hQi=>
MCF7	NX\rUHl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmO2OFghcA>?		M2mxemdKRTBwNEWg{txO	MlPmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMUm1OVUoRjJ2MUG5OVU2RC:jPh?=
MDA-MB-435	NF3QXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{nMU\|Q5KGh?		MmLFS2k:OC56ODFOwG0>	M2n2PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUG5OVU2Lz5{NEGxPVU2PTxxYU6=
AsPC1	NUnucpRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXezNEDPxE1?	NVXkPJhVPDhiaB?=	NGrJXZFFVVOR	MorhTWM2OD1\|Lk[2JO69VQ>?	NGjmOGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG4OVM4QCd-MkSxPFU{Pzh:L3G+
Jurkat E6.1	MofTT4lv[XOnIFHzd4F6		NIrBe4IzKGh?	MoDnSG1UVw>?	MYTJcohq[mm2aX;uJI9nKEiGQVO0JJdqfGhiSVO1NEBw\iByLkC0JO69VQ>?	M4LIVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mk[xPFYzLz5{NEK2NVg3OjxxYU6=
KG1	M3nCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVy0PEBp		NXPIeVFMUUN3ME2xMlE2KM7:TR?=	NVfJe2RbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NlUxODNpPkK0OVI2ODB\|PD;hQi=>
HEL	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MormOFghcA>?	MmX3SG1UVw>?	MWDJR\|UxRTBwNEmg{txO	NHfZUXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[5OFA2PSd-MkS2PVQxPTV:L3G+
HSC3	NHXseWJEgXSxdH;4bYMhSXO\|YYm=		M1H6dlEzKGh?	MnHOSG1UVw>?	MVnJR\|UxRTBwN{Gg{txO	NFPuNWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe2OlU3OCd-MkS3OlY2PjB:L3G+
HT-29	M1njSmN6fG:2b4jpZ{BCe3OjeR?=		NYHNSIUxOTJiaB?=	NWW3OJpkTE2VTx?=	MofiTWM2OD1yLkeyJO69VQ>?	NWHtZ21WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlY2PjBpPkK0O\|Y3PTZyPD;hQi=>
KB	MXvDfZRwfG:6aXOgRZN{[Xl?		NH7wd2EyOiCq	MlviSG1UVw>?	MXLJR\|UxRTBwN{Wg{txO	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4NkW2NEc,OjR5Nk[1OlA9N2F-
H460	MkXuR5l1d3SxeHnjJGF{e2G7		M1TNTVEzKGh?	MmC3SG1UVw>?	M{DsWmlEPTB;MD64NkDPxE1?	NXm1RnBCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlY2PjBpPkK0O\|Y3PTZyPD;hQi=>
MONE1	Mn:zR5l1d3SxeHnjJGF{e2G7		NVHVR2ZnOTJiaB?=	NH23R\|VFVVOR	M3SyT2lEPTB;MT6xPEDPxE1?	NFzRVVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe2OlU3OCd-MkS3OlY2PjB:L3G+
MKN45	MnT4R5l1d3SxeHnjJGF{e2G7		MnXDNVIhcA>?	M37qbWROW09?	MUTJR\|UxRTFwMkWg{txO	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4NkW2NEc,OjR5Nk[1OlA9N2F-
TSGH	MlfsR5l1d3SxeHnjJGF{e2G7		NGW1TmkyOiCq	MnztSG1UVw>?	MV;JR\|UxRTJwMEmg{txO	NYK3UVNTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlY2PjBpPkK0O\|Y3PTZyPD;hQi=>
HL60	NV36VYNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mm\jO\|IhcA>?	MXvEUXNQ	MoniS2k2OD1yLkmzJO69VQ>?	NXrpT29MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA2ODBpPkK0PVAxPTByPD;hQi=>
HEK293	MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV;Ydo81PzJiaB?=	M2fQTmROW09?	MoTVS2k2OD1zMzFOwG0>	Mlr0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC1NFAoRjJ2OUCwOVAxRC:jPh?=
Jurkat	NFzm[IlEgXSxdH;4bYMhSXO\|YYm=	M1L5ZlExOCEQvF2=	M2LJPVczKGh?		M{CxcWdKPTB;MD65JO69VQ>?	NHrMUJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFc1Oyd-MkS5NFA4PDN:L3G+
GM15850	Ml;NT4lv[XOnIFHzd4F6	M3TxeFIvPSEQvF2=	MkHlPVYhcA>?	NXXKRmdWTE2VTx?=	MYrkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{BtgXOrbnWgNVQh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NXjGUmV3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NlE{PjdpPkG2PVIyOzZ5PD;hQi=>
GM15850	M2jVXmtqdmG\|ZTDBd5NigQ>?	M{LEWVIvPSEQvF2=	NX3iS\|dVQTZiaB?=	NHniUFhFVVOR	MnW4[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFUh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	M3TmXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUKxN\|Y4Lz5zNkmyNVM3PzxxYU6=
GM15850	NWq0ZXZyU2mwYYPlJGF{e2G7	MX[yMlUh\|ryP	NYPr[2JUQTZiaB?=	NYHYN5dxTE2VTx?=	NFLDflZld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJPCCueYPpcoUhOTJiYXPleJlt[XSrb36gc4YhTliQIHflcoU>	NVq2V2RFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NlE{PjdpPkG2PVIyOzZ5PD;hQi=>
GM15850	MXXLbY5ie2ViQYPzZZk>	M{nsRVIvPSEQvF2=	M4\Xdlk3KGh?	NI\BR21FVVOR	MWTkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{BtgXOrbnWgPUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	M4HkdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUKxN\|Y4Lz5zNkmyNVM3PzxxYU6=
GM15850	MULLbY5ie2ViQYPzZZk>	NFrkOYQzNjVizszN	NHLVPYc6PiCq	NF\x[5JFVVOR	MnTS[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFgh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NUPufZA5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NlE{PjdpPkG2PVIyOzZ5PD;hQi=>
GM15850	NGrmRVZMcW6jc3WgRZN{[Xl?	NHrPfVkzNjVizszN	M4e1R\|k3KGh?	M4PDVGROW09?	M3rCWIRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UAyPiCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	NXLJV\|dQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NlE{PjdpPkG2PVIyOzZ5PD;hQi=>
GM15850	MY\GeY5kfGmxbjDBd5NigQ>?	NWi0S3R3PSEQvF2=	Mnz0NVIhcA>?	NIDCXllFVVOR	MVvoZZMhdm9iZX\m[YN1KG:wIF\YUkBuWk6DIHX4dJJme3Orb36=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjl{MUO2O{c,OTZ7MkGzOlc9N2F-
U937	M2n1SWtqdmG\|ZTDBd5NigQ>?	NV[4VWQ5PSEQvF2=	MkXINlQhcA>?	M4LTUWROW09?	M3i1U4hieyCwbzDl[oZm[3Rib36gZYxxcGFidIXieYxqdiCjY3X0fYxifGmxbh?=	M3PCWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NES3O\|UxLz5zN{S0O\|c2ODxxYU6=
U937	Mlz5T4lv[XOnIFHzd4F6	NF;HPVgyKM7:TR?=	MV[yOEBp	M4nrPWROW09?	MmfrbIF{KG6xIHXm[oVkfCCxbjDhcJBp[SC2dXL1cIlvKGGlZYT5cIF1cW:w	Mm\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2NEe3OVAoRjF5NES3O\|UxRC:jPh?=
PANC1	MV3GeY5kfGmxbjDBd5NigQ>?	MWCxJO69VQ>?	NVPGdnNvOjRiaB?=		NHP4R5Fld2W\|IH7veEBqdmO{ZXHz[UBqdiCyMkfrbZAyKGenbnWg[ZhxemW\|c3nvci=>	M4DzPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUi4O\|Q1Lz5zN{W4PFc1PDxxYU6=
PANC1	Mm\tSpVv[3Srb36gRZN{[Xl?	M3vTOVEh\|ryP	M3rmbVQ5KCCq		NWfHWXZZ\G:nczDuc5QhcW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44>	MlvKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3OEi3OFQoRjF5NUi4O\|Q1RC:jPh?=
Caco-2	MYXGeY5kfGmxbjDBd5NigQ>?	NUnG[GlCPSEQvF2=	Ml:4NlQhcA>?	MV;EUXNQ	MnPB[I9meyCwb4SgbY5lfWOnIGCyNXdCTjFiZ3Xu[UBmgHC{ZYPzbY9v	MkPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO4OFAoRjJyMUSzPFQxRC:jPh?=
SCC4	NHTQTHRHfW6ldHnvckBCe3OjeR?=	M2DvRlEh\|ryP	NVPBTJNQOTBibXnu	MXvEUXNQ	NX\mVHpNcGG\|IH7vJIFod26rc4SgZYN1cX[rdImgZZQhXkSUIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCFWWCyOEBo\W6nIHX4dJJme3Orb36=	M2DJWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEWyNlI2Lz5{MES1NlIzPTxxYU6=
A549	NEXaSZZHfW6ldHnvckBCe3OjeR?=	M33FdlUh\|ryP	NXewSIRNOyCq	NXjtfGE1TE2VTx?=	NHzRflVld2W\|IH7veEBqdmS3Y3WgZZV1d3CqYXf5JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIFzDN2lK	M2OxOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEW1NlA5Lz5{MEi1OVIxQDxxYU6=
HCT116	NX;uV446U2mwYYPlJGF{e2G7	NFL1TZYxNjNizszN	NF;LTpI{OCCq	MWPEUXNQ	MV7kc4V{KG6xdDDpcohq[mm2IFjERWMyKGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBpcXO2b37lJGg{UzliYXPleJlt[XSrb36=	M{TKbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEiwOlQ4Lz5{MUC4NFY1PzxxYU6=
HepG2	M{DOfWZ2dmO2aX;uJGF{e2G7	MX[xNEDPxE1?	NXS2doM{OjRiaB?=	MXTEUXNQ	M4XnUoRw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYOgZZN{\XO\|ZXSgZZMhcHmyZYLhZ4V1gWyjdHnvckBw\iCyNUO=	MlvFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3NEi1PFIoRjJzNUS4OVgzRC:jPh?=
GM11272	Mne1SpVv[3Srb36gRZN{[Xl?	MYmwMlEh\|ryP	NETnSIg4OiCq	MXLEUXNQ	NGHqSoVld2W\|IH7veEBz\WGldHn2ZZRmKE2nQ4CyJI12fGGwdDDlfJBz\XO\|aX;u	M3fielxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOESwO\|E3Lz5{MUi0NFcyPjxxYU6=
MDA-MB-231	M4TUW2tqdmG\|ZTDBd5NigQ>?	MoX6NVAh\|ryP	NWrJVmx{PSCvaX6=	NI\5R\|RFVVOR	NHPwc49ld2W\|IH7veEBqdmirYnn0JGhFSUN{YR?=	NHnQ[JE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5N\|Q1QSd-MkO0PVM1PDl:L3G+
MDA-MB-231	MVXLbY5ie2ViQYPzZZk>	NXzvbZI3OSEQvF2=	MofJNlQhcA>?	MmXESG1UVw>?	MVjkc4V{KG6xdDDpcohq[mm2IFjERWM3KGG\|c3Xzd4VlKGG\|IHHj[ZR6dGG2aX;uJIxmfmWuczDv[kB1fWK3bHnu	NYCxPVdbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVM1PDlpPkKzOFk{PDR7PD;hQi=>
K562	NVXRNmViU2mwYYPlJGF{e2G7				Mlza[I9meyCwb4SgbY5pcWKrdDDISGFE	MmPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3OUGxNVEoRjJ\|NUmxNVEyRC:jPh?=
Jurkat	NIDhOnBEgXSxdH;4bYMhSXO\|YYm=	Ml3PNlAh\|ryP	MnXGO\|IhcA>?	NEnOblRFVVOR	NELKZXdvdyCleYTveI95cWOrdImgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44>	MlvrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|MESzOFgoRjJ2M{C0N\|Q5RC:jPh?=
HCT116	NVqybpdvSXCxcITvd4l{KEG\|c3H5	NVfUOWdyOyEQvF2=	NGnWZ4MzPCCq	MoXxSG1UVw>?	NVXFRoRE\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwOVMheHKxdHXpckBt\X[nbB?=	M{HFfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{[2OVYxLz5{NEe2OlU3ODxxYU6=
KASUMI-1	NX3DfFFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjETmFKSzVyPUm5MlE4KG6P	NG\M[GY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
KARPAS-45	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfzdphKSzVyPUG3N{45QSCwTR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
BHT-101	NEjCWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;qSGtmUUN3ME2yOFQvOThibl2=	NEjDcHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
H9	MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYqzWnhKUUN3ME2yOVUvODRibl2=	M1XaNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
PA-1	NGX3d3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vIVGlEPTB;Mki2MlI3KG6P	NWXZe4NJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NEC8	M1LzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH76cXFKSzVyPUK4PU4{QCCwTR?=	MlXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
MHH-PREB-1	NIXZV4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\lWGlEPTB;Mkm0MlU{KG6P	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NB7	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGToeGZKSzVyPUO0OU44PCCwTR?=	M4rhfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
A3-KAW	NUT4[lZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4q5RmlEPTB;NECwMlU6KG6P	M{PDZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NB69	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mor6TWM2OD12MUGuO\|Ehdk1?	NF;E[\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
EoL-1-cell	M37ocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3LRmZKSzVyPUS1OFI2KG6P	NUfEeIZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
CHP-212	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTR3Nz61N{BvVQ>?	NWW0WJU4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
C2BBe1	MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLITWM2OD12N{KuNVkhdk1?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
697	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGP6dlhKSzVyPUS3N{41OSCwTR?=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
BCPAP	NHHnPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTVyMT60NkBvVQ>?	MkLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
L-363	M2i2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonBTWM2OD13MEOuNUBvVQ>?	Mnr0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
ES8	M{D1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfsWpZTUUN3ME21NlMvPTNibl2=	Mmr1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
BE-13	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTqPGpnUUN3ME21NlYvQTZibl2=	Mmn1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
CTB-1	NUm0WXJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnEcZFKSzVyPUWzO{46OiCwTR?=	Mn3xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
HD-MY-Z	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnr0TWM2OD13M{iuNVMhdk1?	M3fz[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NKM-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3q5S2lEPTB;NUS0MlI4KG6P	NVrBeFRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NCI-H720	NIrMV2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PRXGlEPTB;NU[wMlE5KG6P	MkL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
KY821	NFXmUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTV4Mz6yOUBvVQ>?	MlrjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
OVCAR-5	NI\sUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPJTWM2OD13N{[uNVEhdk1?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
CTV-1	NEjCOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDFdlVKSzVyPUW4NU42PiCwTR?=	M2rFfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
P12-ICHIKAWA	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHyxPYVKSzVyPUW5Ok42OSCwTR?=	M{f3bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
DB	M2HIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLESWVMUUN3ME21PVgvPTdibl2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
CHL-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvGZm9iUUN3ME22OFIvODhibl2=	NU\Fb2R[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
A4-Fuk	NX2xRVhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTzTWM2OD14NESuPVEhdk1?	NVTqdZRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
MV-4-11	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\3cmNKSzVyPU[1PU4yKG6P	NIm5Rm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
RPMI-8226	NWThWm9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjUTWM2OD14N{iuNVghdk1?	MmLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NB14	MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTZ7Nj65OUBvVQ>?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
DOHH-2	M2fqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTCZ2ZZUUN3ME23NFYvPjhibl2=	Mn3qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
D-423MG	NUfqbZl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzablNZUUN3ME23NFYvQDlibl2=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
D-283MED	NFPSSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTdzND6xOEBvVQ>?	MkTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
ES1	MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVn1WZVoUUN3ME23NlQvPCCwTR?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
GOTO	NEH6WoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LLcWlEPTB;N{K5MlEzKG6P	NGfhfJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
NCI-H209	M{mxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jMSmlEPTB;N{K5Mlkhdk1?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
MOLT-13	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorvTWM2OD15M{iuPVghdk1?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
ATN-1	NV;UcWFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3Ho[WlEPTB;N{SwMlI5KG6P	MofyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
DU-4475	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LTc2lEPTB;N{WxMlkyKG6P	NUfjR2JpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NB10	NHywRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;YR2lEPTB;N{WxMlkzKG6P	NHzwXVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
KG-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFG2NFFKSzVyPUe3OU41PSCwTR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
MOLT-4	M4nNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3f4[2lEPTB;N{i3MlQ3KG6P	Mn[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
TE-1	NX3uWZJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDqTWM2OD15OUGuNUBvVQ>?	Ml;GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SBC-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1y0emlEPTB;N{mzMlg1KG6P	NWTBSFMyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
HEL	NE[w[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\VTGpKSzVyPUiwOk4xQCCwTR?=	Mlz4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SK-MEL-2	MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRThyOT60OEBvVQ>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
KU812	NFLSdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoSyTWM2OD16MUOuNUBvVQ>?	M{G4dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
RPMI-8866	NFPPWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLXTWM2OD16MUOuOlchdk1?	Ml3kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
ALL-PO	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLBWYFKSzVyPUixOE43PiCwTR?=	MontQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
LU-139	MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWi2OlBIUUN3ME24NlIvQDZibl2=	NHXNSJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
RS4-11	NGGzdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3vTWM2OD16M{KuOFUhdk1?	MkjOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
EW-18	NGC3OYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3MT4VKSzVyPUizNk46PiCwTR?=	Mn\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
P30-OHK	M4K4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4e2O2lEPTB;OEO1Mlchdk1?	NW\VVmQ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
D-566MG	NHjRN2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIP5RoJKSzVyPUizPE43OiCwTR?=	NXPONFBORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
HSC-4	NX3IUlZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\PfGt6UUN3ME24OFYvPTFibl2=	NF7ITFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
QIMR-WIL	M4H2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTh4Mj6wN{BvVQ>?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
SW954	NF[weVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjQZ\|NoUUN3ME24OlMvOTZibl2=	M{K4N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
HGC-27	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTh5Mj6zOEBvVQ>?	NEP0UlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HH	M3vNPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nnPWlEPTB;OEm0MlEzKG6P	MoHrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
KE-37	NUHmW3FkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjHWJlKSzVyPUi5OE43OiCwTR?=	MkTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SK-N-DZ	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXiTWM2OD17MECuOFMhdk1?	NE[xS4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
J-RT3-T3-5	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4L1ZmlEPTB;OUGwMlQ6KG6P	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
A427	NEnKfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPsWlBKSzVyPUmyNE45PCCwTR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
ECC10	NGfRSHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rhdmlEPTB;OUS1Mlg4KG6P	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
EW-1	NHrjcpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzxTWM2OD17NEeuNlYhdk1?	NWjSTlBVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
MIA-PaCa-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXv1XHN2UUN3ME25OFkvOTJibl2=	NWDOUlEzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
HCC2218	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrPT2FKSzVyPUm1PE41QCCwTR?=	MorLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
HAL-01	M4Du[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1j5fGlEPTB;OU[4MlA1KG6P	NYL0XIFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
RD	NX;3PZFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTl5ND60OUBvVQ>?	Mkf2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SK-N-AS	MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfKW4s5UUN3ME25PFgvOSCwTR?=	NWfTOZRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
ML-2	Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PTU2lEPTB;MT6wNFQxPyEQvF2=	NVfM[GpmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
MEL-HO	MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7oboJKUUN3ME2xMlAxPTh{IN88US=>	MmLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
MS-1	MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PqWWlEPTB;MT6wNFYyPyEQvF2=	Mmf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NCI-SNU-1	M1f2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjXeWtKSzVyPUGuNFI{OzFizszN	Mk\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
8505C	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLYTWM2OD1zLkCyN\|MyKM7:TR?=	MnzqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
MN-60	M3P6b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTFwMEK2PEDPxE1?	NFK5cWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
SAS	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfOb3BKSzVyPUGuNFQxQDFizszN	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
EFM-19	NYe0cGVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjEW4JKSzVyPUGuNFQ5PzlizszN	NYTwcmMyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
Ca9-22	Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jOXWlEPTB;MT6wOVExPyEQvF2=	MkTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NBsusSR	NWTBPVNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HERWlEPTB;MT6wOVE3PiEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NB13	Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\LfJNKSzVyPUGuNFU2ODFizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
SF295	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\BTWM2OD1zLkC2OlI1KM7:TR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
U-2-OS	M3LFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTMTWM2OD1zLkC3PVEyKM7:TR?=	NU\5UpA{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NCI-H526	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTFwMEiyPVEh\|ryP	NXzPclZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
KMOE-2	NIn3XpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnQdZRwUUN3ME2xMlA6PDJ{IN88US=>	NF74fGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
RCM-1	NY\HbIxsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjTXY91UUN3ME2xMlEzOTB{IN88US=>	NETtWVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
MC116	NXnOU\|V5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlG5TWM2OD1zLkGzOlIyKM7:TR?=	Mnr3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
NCI-H1092	M2\KUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjRTWM2OD1zLkG1OFA3KM7:TR?=	MoPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
EW-3	MnfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVy2dpRjUUN3ME2xMlE4OjF{IN88US=>	NInTN\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HCT-116	M1fRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTFwMUe3OUDPxE1?	M4ftfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
MC-IXC	NIfWfoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nrPGlEPTB;MT6xO\|g5OSEQvF2=	M3L4RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
LB1047-RCC	NHLST4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fiVmlEPTB;MT6xPFMyOiEQvF2=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
VM-CUB-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIWyW3JKSzVyPUGuNVkyODhizszN	NXzicJE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NB5	MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4H5d2lEPTB;MT6xPVg2PiEQvF2=	NWfvPHplRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SKG-IIIa	M1OzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHOWVJKSzVyPUGuNlM1PjRizszN	M4flcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
HO-1-N-1	MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojVTWM2OD1zLkKzPFM2KM7:TR?=	NFT3WYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
EFO-27	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVn6W2duUUN3ME2xMlI2ODR\|IN88US=>	Mn3NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
MHH-NB-11	NYPmdJVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;leYZNUUN3ME2xMlI5OzJ7IN88US=>	Mn\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
SW620	NFXjeHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HIWWlEPTB;MT6yPVAyQCEQvF2=	NUjmbGFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
MOLT-16	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTFwMkm3PVch\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NTERA-S-cl-D1	MmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnLSYtWUUN3ME2xMlMyPzZzIN88US=>	NVuwbI44RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
VA-ES-BJ	NHLJZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELVeW1KSzVyPUGuN\|I1PzdizszN	NFnvUVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HCC1419	NHHwTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2GzUGlEPTB;MT6zOFAzPyEQvF2=	NH3EVnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
NCI-H69	NGG3NIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWD1dmRpUUN3ME2xMlM1OTF{IN88US=>	NYmzepJGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
DEL	MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDyOHdyUUN3ME2xMlM2OTZ{IN88US=>	M4LUeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
LXF-289	NELi[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17TVWlEPTB;MT6zOVI1KM7:TR?=	NFrGeHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
EW-11	M4HVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIm1dJFKSzVyPUGuN\|YxOjZizszN	M1fhT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
KP-4	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTFwM{ewPFUh\|ryP	M{fkeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NOS-1	Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;uTWM2OD1zLkSxNVk1KM7:TR?=	NEjPb5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
SK-NEP-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrxTWM2OD1zLkSxOlk{KM7:TR?=	NUPaSo9QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
LAMA-84	MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTFwNEO5OFUh\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
ES5	NHT2TXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTFwNESzJO69VQ>?	MkD1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
HuO9	M4C3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTFwNEWzOlIh\|ryP	NGH4e4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
COLO-684	NFfScnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTFwNE[xNVgh\|ryP	NHHSO2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
EW-24	MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\CTWM2OD1zLkS2OVMyKM7:TR?=	NXXXbW55RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
BV-173	NX\lVoNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTFwNEeyPVEh\|ryP	M3roNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-H1770	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTFwNEi1N\|Yh\|ryP	NYXTd5hORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
HuP-T4	MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDHTWM2OD1zLkS5N{DPxE1?	NH:4bJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
TYK-nu	Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUP6dZV1UUN3ME2xMlQ6QDVzIN88US=>	NFPQeVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
YH-13	NIL4[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTFwNEm4PVQh\|ryP	Mlu4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
H4	NFv2PJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTFwNUC5NVIh\|ryP	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
OVCAR-8	M{fjPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfuTWM2OD1zLkW0OFc4KM7:TR?=	M3\M[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-H23	NHz6eHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTFwNUS2OFUh\|ryP	NI[3VW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
ES7	NXTsZ\|NJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH[1NZJKSzVyPUGuOVQ4PzNizszN	M1vBSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
COR-L88	M4flUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{[3W2lEPTB;MT61OlQzPCEQvF2=	Mn23QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
TI-73	NHTLUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjUTWM2OD1zLkW5NFYh\|ryP	MkTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
RT-112	NVjPfoVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTFwNUmyPFQh\|ryP	M{joT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
HuO-3N1	M{jiPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHn0VIZKSzVyPUGuOVk{QDVizszN	NHXlTpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HC-1	MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPhTWM2OD1zLkW5PFY3KM7:TR?=	NXXsfJZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
HT55	NH:yZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHGVodKSzVyPUGuOlUyOzFizszN	M{DDVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
IA-LM	M{Lw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPCfXNKSzVyPUGuOlkzPzhizszN	MlzLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
EM-2	NFTHUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTFwN{CwNVQh\|ryP	NWHKXYJTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
MHH-ES-1	MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3MO4lFUUN3ME2xMlcxPDN3IN88US=>	M2LrO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
CAL-27	M4TqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HlWWlEPTB;MT63NFYzOSEQvF2=	M1TFb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
COLO-800	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\MOndKSzVyPUGuO\|EyPzlizszN	NIXzXIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HCE-T	MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkmyTWM2OD1zLkexOUDPxE1?	M3PQflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
CAMA-1	Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DweWlEPTB;MT63NVk4OSEQvF2=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
LOXIMVI	NUHmfIF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXUeVQ3UUN3ME2xMlczOTFizszN	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
NH-12	Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTFwN{K2PVEh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
TCCSUP	NEDCO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTFwN{K4Nlkh\|ryP	MoPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
MDA-MB-361	MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF74NZBKSzVyPUGuO\|MyPTdizszN	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
EW-16	NYDUUZZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2n4RmlEPTB;MT63OFExPyEQvF2=	NVTSNmxJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
SNU-423	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTFwN{W4Nlch\|ryP	NInZW4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
Daoy	NVvt[2d{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jVbGlEPTB;MT63OlMyQSEQvF2=	M1XZbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
ES4	M{K3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTFwN{i3OFEh\|ryP	NHH5cpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
PFSK-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fzUWlEPTB;MT64NFM4KM7:TR?=	NXrFOpJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
ES3	NHr6UZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfPR2hkUUN3ME2xMlgzPjhzIN88US=>	MlGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
ONS-76	MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nt[mlEPTB;MT64Nlg6PyEQvF2=	MnrQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
JVM-3	NXPCToVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTFwOEW0OVEh\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
OS-RC-2	NYS5RWxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU[4Z\|g4UUN3ME2xMlg4OTVzIN88US=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
COLO-320-HSR	MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\SPZdKSzVyPUGuPFgyQTdizszN	NFrRUFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HN	M{jpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjJ[HFwUUN3ME2xMlg5PzJ3IN88US=>	NHPOZlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HT	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHr5NG5KSzVyPUGuPFg6PDdizszN	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
LoVo	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHiWJhKSzVyPUGuPFk5OSEQvF2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
CGTH-W-1	M13jSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DwSmlEPTB;MT64PVk1PiEQvF2=	NXfiVZU{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
NB6	NUPIZXdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrWd21KSzVyPUGuPVEzQThizszN	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
EW-22	M2PkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPHUY5nUUN3ME2xMlkzQDh5IN88US=>	MkW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
ES6	MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TDOWlEPTB;MT65N\|Y{OSEQvF2=	NHzxTIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
SCC-15	Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrPc4dKSzVyPUGuPVM5OTlizszN	NEjZfms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
HL-60	NX7JUGNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojTTWM2OD1zLkmzPVAzKM7:TR?=	NIf6dFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
human HOP-92	NHjYXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIj2OnNKSzVyPUGuPVQxPjVizszN	M{nseVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
SW626	NVj3W5FDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLQTWM2OD1zLkm0PFk6KM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5PE8oRlODTlfFVlww[T5?
HEC-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\OemlEPTB;MT65OVM3KM7:TR?=	MmThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVgwLz6VQV7HSXI9N2F-
LB2241-RCC	NX3afFBFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTITWM2OD1zLkm4NlMyKM7:TR?=	NESx[nk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6QC9pPmPBUmdGWjxxYU6=
Ramos-2G6-4C10	NHrXXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TjXWlEPTB;MT65PVQ6OyEQvF2=	NYjDbGxIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQThxJ{7TRW5ITVJ:L3G+
A101D	NVjhfW1PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTrNJVLUUN3ME2yMlIxOzB\|IN88US=>	M3HRdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk5Nyd-U1HOS2VTRC:jPh?=
NCI-H446	M1vZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7

研究领域

产品类型